{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":null,"value":72},{"name":null,"value":26},{"name":null,"value":40},{"name":null,"value":27},{"name":null,"value":80},{"name":null,"value":28},{"name":null,"value":35},{"name":null,"value":10},{"name":null,"value":134},{"name":null,"value":121},{"name":null,"value":78},{"name":null,"value":29},{"name":null,"value":32},{"name":null,"value":31},{"name":null,"value":33},{"name":null,"value":126},{"name":null,"value":36},{"name":null,"value":82},{"name":null,"value":37},{"name":null,"value":115},{"name":"Government Matters","value":"cg-2"},{"name":null,"value":1},{"name":null,"value":6},{"name":null,"value":71},{"name":null,"value":21},{"name":null,"value":23},{"name":null,"value":116},{"name":null,"value":24},{"name":null,"value":135},{"name":null,"value":25},{"name":null,"value":110},{"name":null,"value":20},{"name":null,"value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":null,"value":129},{"name":null,"value":2},{"name":null,"value":38},{"name":null,"value":3},{"name":null,"value":5},{"name":null,"value":19},{"name":null,"value":7},{"name":null,"value":4},{"name":null,"value":136},{"name":null,"value":13},{"name":null,"value":14},{"name":null,"value":15},{"name":null,"value":17},{"name":null,"value":18},{"name":null,"value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":null,"value":133},{"name":null,"value":106},{"name":null,"value":124},{"name":null,"value":111},{"name":null,"value":132},{"name":null,"value":131},{"name":null,"value":102},{"name":null,"value":125},{"name":null,"value":127},{"name":null,"value":107},{"name":null,"value":112},{"name":null,"value":105},{"name":null,"value":109},{"name":null,"value":103},{"name":null,"value":128},{"name":null,"value":123},{"name":null,"value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"23","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":null,"per_page":12,"people":[{"id":436413,"version":1,"owner_type":"Person","owner_id":3400,"payload":{"bio":"\u003cp\u003eSajid Ahmed is a Partner in the London office of King \u0026amp; Spalding.\u0026nbsp; He specialises in international arbitration and trade matters.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSajid\u0026rsquo;s cases are typically high-value complex disputes, often dealing with political, commercial and/or social issues involving State owned entities and governments. \u0026nbsp;Sajid represents both claimants and respondents in arbitral proceedings under all the major arbitral rules and institutions including the ICC, LCIA, ICSID and UNCITRAL. While sector agnostic, Sajid is particularly well-known for handling disputes in energy, mining, life sciences, financial services, and media where he is listed as a \u0026ldquo;\u003cem\u003ename to note\u003c/em\u003e\u0026rdquo;.\u0026nbsp; Although experienced across various geographies, Sajid is prominently known for his disputes work in India, Turkey and Central Asia. Correspondingly, Sajid's global clientele include multi-nationals and State/State entities in those regions.\u0026nbsp; As a recipient of a number of recognitions from legal directories and industry commentators over the years, \u0026nbsp;Sajid is described as having \u0026ldquo;\u003cem\u003eindispensable leadership\u003c/em\u003e\u0026rdquo;\u0026nbsp;(IBLJ (2022)) and as being \u0026ldquo;\u003cem\u003ean excellent lawyer with good business acumen and understands client\u0026rsquo;s perspective and overall business context and comes out with pragmatic solutions\u003c/em\u003e\u0026rdquo; (Legal 500 UK, 2021).\u003c/p\u003e\n\u003cp\u003eSajid also has notable experience in international trade matters including export controls and sanctions. He assists clients prepare disclosures of export control and economic sanctions laws violations and represents them in regulatory investigations.\u003c/p\u003e","slug":"sajid-ahmed","email":"sahmed@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eRecent Representations \u0026ndash; Arbitration Matters\u003c/strong\u003e\u003cbr /\u003eAn Asian\u0026nbsp;\u003cstrong\u003eExploration \u0026amp; Production company\u0026nbsp;\u003c/strong\u003ein an ad hoc UNCITRAL\u0026nbsp;arbitration against the Government of India with respect to cross-boundary gas migration issues.\u003c/p\u003e","\u003cp\u003eAn\u0026nbsp;\u003cstrong\u003eIndian pharmaceuticals company\u0026nbsp;\u003c/strong\u003ein a LCIA arbitration in London against a major Canadian generics producer with respect to a breach of exclusivity provisions in a licence agreement.\u003c/p\u003e","\u003cp\u003eA significant\u0026nbsp;\u003cstrong\u003eoil \u0026amp; gas company\u003c/strong\u003e\u0026nbsp;in two ad hoc UNCITRAL arbitrations against an Asian sovereign state, one relating to the company\u0026rsquo;s right to cost recovery under a PSC and the other relating to gas pricing.\u003c/p\u003e","\u003cp\u003eThe\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eRepublic of Turkey\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eTurkish state-owned\u003c/strong\u003e\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eentity BOTAS\u003c/strong\u003e\u0026nbsp;in an ICC arbitration in Paris against the Republic of Iraq in relation to a dispute concerning an intergovernmental pipeline agreement.\u003c/p\u003e","\u003cp\u003eA significant\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eTurkish E\u0026amp;P company\u003c/strong\u003e\u0026nbsp;against the Republic of Kazakhstan in an ICSID arbitration brought under the Turkey\u0026ndash;Kazakhstan bilateral investment treaty relating to a tax stabilization clause.\u003c/p\u003e","\u003cp\u003eAn\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eIndian electrical engineering company\u003c/strong\u003e\u0026nbsp;in an ICC arbitration in London against a UK company involving claims of defective products provided pursuant to a Supply Agreement.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultinational life sciences company\u003c/strong\u003e\u0026nbsp;against a US company in an ICC arbitration in London concerning a breach of a licence agreement with respect to the marketing of a biopharmaceutical product.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant Asian company\u003c/strong\u003e\u0026nbsp;in an LCIA arbitration in London against a U.S. investment bank relating to breaches of a services agreement in connection with an M\u0026amp;A deal.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant pharmaceutical company\u003c/strong\u003e\u0026nbsp;in an ICC arbitration proceeding in New York against a German company relating to breaches of a manufacturing and supply agreement.\u003c/p\u003e","\u003cp\u003e\u003cstrong data-redactor-tag=\"strong\"\u003eRecent Representations \u0026ndash; Export Controls and Sanctions Matters\u003c/strong\u003e\u003cbr /\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emajor financial institution\u003c/strong\u003e\u0026nbsp;on EU-Russia sanctions concerning the provision of loans, capital market instruments and other types of financial instruments to Russia-related persons.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emajor Middle East petrochemicals company\u003c/strong\u003e\u0026nbsp;on EU sanctions with respect to Iran and Syria and potential exposure based on business transactions with Iranian and Syrian entities.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant Middle East sovereign wealth fund\u003c/strong\u003e\u0026nbsp;on the successful de-listing of one its associated companies from the EU sanctions list.\u003c/p\u003e","\u003cp\u003eA major Asian oil and gas company in connection with the EU relaxation of sanctions on investments in the Iranian hydrocarbons sector and on Iranian oil exports under the Joint Comprehensive Plan of Action.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant aircraft manufacturer\u003c/strong\u003e\u0026nbsp;on export sales of aircraft and aircraft parts from certain EU countries to the Middle East region and South America.\u003c/p\u003e","\u003cp\u003eAn\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eaerospace client\u003c/strong\u003e\u0026nbsp;in its UK voluntary self-disclosures due to potential violation of UK/EU export control rules. The representation included review of customer due-diligence policies and procedures as well as sales contracts for the purposes of export controls and sanctions compliance.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":12}]},"expertise":[{"id":25,"guid":"25.capabilities","index":0,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":3,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":4,"source":"capabilities"},{"id":14,"guid":"14.capabilities","index":5,"source":"capabilities"},{"id":1142,"guid":"1142.smart_tags","index":6,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":7,"source":"smartTags"},{"id":128,"guid":"128.capabilities","index":8,"source":"capabilities"},{"id":108,"guid":"108.capabilities","index":9,"source":"capabilities"},{"id":1327,"guid":"1327.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"Ahmed","nick_name":"Sajid","clerkships":[],"first_name":"Sajid","title_rank":9999,"updated_by":174,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"“Indispensable Leadership” ","detail":"India Business Law Journal (2022)"},{"title":"Recognized as “an excellent lawyer with good business acumen\"","detail":"LEGAL 500, 2021"},{"title":"\"Understands client’s perspective and overall business context and comes out with pragmatic solutions\" ","detail":"Legal 500, 2021"},{"title":"Recognized as “a name to note”","detail":"LEGAL 500, 2021"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eSajid Ahmed is a Partner in the London office of King \u0026amp; Spalding.\u0026nbsp; He specialises in international arbitration and trade matters.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSajid\u0026rsquo;s cases are typically high-value complex disputes, often dealing with political, commercial and/or social issues involving State owned entities and governments. \u0026nbsp;Sajid represents both claimants and respondents in arbitral proceedings under all the major arbitral rules and institutions including the ICC, LCIA, ICSID and UNCITRAL. While sector agnostic, Sajid is particularly well-known for handling disputes in energy, mining, life sciences, financial services, and media where he is listed as a \u0026ldquo;\u003cem\u003ename to note\u003c/em\u003e\u0026rdquo;.\u0026nbsp; Although experienced across various geographies, Sajid is prominently known for his disputes work in India, Turkey and Central Asia. Correspondingly, Sajid's global clientele include multi-nationals and State/State entities in those regions.\u0026nbsp; As a recipient of a number of recognitions from legal directories and industry commentators over the years, \u0026nbsp;Sajid is described as having \u0026ldquo;\u003cem\u003eindispensable leadership\u003c/em\u003e\u0026rdquo;\u0026nbsp;(IBLJ (2022)) and as being \u0026ldquo;\u003cem\u003ean excellent lawyer with good business acumen and understands client\u0026rsquo;s perspective and overall business context and comes out with pragmatic solutions\u003c/em\u003e\u0026rdquo; (Legal 500 UK, 2021).\u003c/p\u003e\n\u003cp\u003eSajid also has notable experience in international trade matters including export controls and sanctions. He assists clients prepare disclosures of export control and economic sanctions laws violations and represents them in regulatory investigations.\u003c/p\u003e","matters":["\u003cp\u003e\u003cstrong\u003eRecent Representations \u0026ndash; Arbitration Matters\u003c/strong\u003e\u003cbr /\u003eAn Asian\u0026nbsp;\u003cstrong\u003eExploration \u0026amp; Production company\u0026nbsp;\u003c/strong\u003ein an ad hoc UNCITRAL\u0026nbsp;arbitration against the Government of India with respect to cross-boundary gas migration issues.\u003c/p\u003e","\u003cp\u003eAn\u0026nbsp;\u003cstrong\u003eIndian pharmaceuticals company\u0026nbsp;\u003c/strong\u003ein a LCIA arbitration in London against a major Canadian generics producer with respect to a breach of exclusivity provisions in a licence agreement.\u003c/p\u003e","\u003cp\u003eA significant\u0026nbsp;\u003cstrong\u003eoil \u0026amp; gas company\u003c/strong\u003e\u0026nbsp;in two ad hoc UNCITRAL arbitrations against an Asian sovereign state, one relating to the company\u0026rsquo;s right to cost recovery under a PSC and the other relating to gas pricing.\u003c/p\u003e","\u003cp\u003eThe\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eRepublic of Turkey\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eTurkish state-owned\u003c/strong\u003e\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eentity BOTAS\u003c/strong\u003e\u0026nbsp;in an ICC arbitration in Paris against the Republic of Iraq in relation to a dispute concerning an intergovernmental pipeline agreement.\u003c/p\u003e","\u003cp\u003eA significant\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eTurkish E\u0026amp;P company\u003c/strong\u003e\u0026nbsp;against the Republic of Kazakhstan in an ICSID arbitration brought under the Turkey\u0026ndash;Kazakhstan bilateral investment treaty relating to a tax stabilization clause.\u003c/p\u003e","\u003cp\u003eAn\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eIndian electrical engineering company\u003c/strong\u003e\u0026nbsp;in an ICC arbitration in London against a UK company involving claims of defective products provided pursuant to a Supply Agreement.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultinational life sciences company\u003c/strong\u003e\u0026nbsp;against a US company in an ICC arbitration in London concerning a breach of a licence agreement with respect to the marketing of a biopharmaceutical product.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant Asian company\u003c/strong\u003e\u0026nbsp;in an LCIA arbitration in London against a U.S. investment bank relating to breaches of a services agreement in connection with an M\u0026amp;A deal.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant pharmaceutical company\u003c/strong\u003e\u0026nbsp;in an ICC arbitration proceeding in New York against a German company relating to breaches of a manufacturing and supply agreement.\u003c/p\u003e","\u003cp\u003e\u003cstrong data-redactor-tag=\"strong\"\u003eRecent Representations \u0026ndash; Export Controls and Sanctions Matters\u003c/strong\u003e\u003cbr /\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emajor financial institution\u003c/strong\u003e\u0026nbsp;on EU-Russia sanctions concerning the provision of loans, capital market instruments and other types of financial instruments to Russia-related persons.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emajor Middle East petrochemicals company\u003c/strong\u003e\u0026nbsp;on EU sanctions with respect to Iran and Syria and potential exposure based on business transactions with Iranian and Syrian entities.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant Middle East sovereign wealth fund\u003c/strong\u003e\u0026nbsp;on the successful de-listing of one its associated companies from the EU sanctions list.\u003c/p\u003e","\u003cp\u003eA major Asian oil and gas company in connection with the EU relaxation of sanctions on investments in the Iranian hydrocarbons sector and on Iranian oil exports under the Joint Comprehensive Plan of Action.\u003c/p\u003e","\u003cp\u003eA\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003esignificant aircraft manufacturer\u003c/strong\u003e\u0026nbsp;on export sales of aircraft and aircraft parts from certain EU countries to the Middle East region and South America.\u003c/p\u003e","\u003cp\u003eAn\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eaerospace client\u003c/strong\u003e\u0026nbsp;in its UK voluntary self-disclosures due to potential violation of UK/EU export control rules. The representation included review of customer due-diligence policies and procedures as well as sales contracts for the purposes of export controls and sanctions compliance.\u003c/p\u003e"],"recognitions":[{"title":"“Indispensable Leadership” ","detail":"India Business Law Journal (2022)"},{"title":"Recognized as “an excellent lawyer with good business acumen\"","detail":"LEGAL 500, 2021"},{"title":"\"Understands client’s perspective and overall business context and comes out with pragmatic solutions\" ","detail":"Legal 500, 2021"},{"title":"Recognized as “a name to note”","detail":"LEGAL 500, 2021"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6066}]},"capability_group_id":3},"created_at":"2025-09-02T04:52:36.000Z","updated_at":"2025-09-02T04:52:36.000Z","searchable_text":"Ahmed{{ FIELD }}{:title=\u0026gt;\"“Indispensable Leadership” \", :detail=\u0026gt;\"India Business Law Journal (2022)\"}{{ FIELD }}{:title=\u0026gt;\"Recognized as “an excellent lawyer with good business acumen\\\"\", :detail=\u0026gt;\"LEGAL 500, 2021\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Understands client’s perspective and overall business context and comes out with pragmatic solutions\\\" \", :detail=\u0026gt;\"Legal 500, 2021\"}{{ FIELD }}{:title=\u0026gt;\"Recognized as “a name to note”\", :detail=\u0026gt;\"LEGAL 500, 2021\"}{{ FIELD }}Recent Representations – Arbitration MattersAn Asian Exploration \u0026amp; Production company in an ad hoc UNCITRAL arbitration against the Government of India with respect to cross-boundary gas migration issues.{{ FIELD }}An Indian pharmaceuticals company in a LCIA arbitration in London against a major Canadian generics producer with respect to a breach of exclusivity provisions in a licence agreement.{{ FIELD }}A significant oil \u0026amp; gas company in two ad hoc UNCITRAL arbitrations against an Asian sovereign state, one relating to the company’s right to cost recovery under a PSC and the other relating to gas pricing.{{ FIELD }}The Republic of Turkey and Turkish state-owned entity BOTAS in an ICC arbitration in Paris against the Republic of Iraq in relation to a dispute concerning an intergovernmental pipeline agreement.{{ FIELD }}A significant Turkish E\u0026amp;P company against the Republic of Kazakhstan in an ICSID arbitration brought under the Turkey–Kazakhstan bilateral investment treaty relating to a tax stabilization clause.{{ FIELD }}An Indian electrical engineering company in an ICC arbitration in London against a UK company involving claims of defective products provided pursuant to a Supply Agreement.{{ FIELD }}A multinational life sciences company against a US company in an ICC arbitration in London concerning a breach of a licence agreement with respect to the marketing of a biopharmaceutical product.{{ FIELD }}A significant Asian company in an LCIA arbitration in London against a U.S. investment bank relating to breaches of a services agreement in connection with an M\u0026amp;A deal.{{ FIELD }}A significant pharmaceutical company in an ICC arbitration proceeding in New York against a German company relating to breaches of a manufacturing and supply agreement.{{ FIELD }}Recent Representations – Export Controls and Sanctions MattersA major financial institution on EU-Russia sanctions concerning the provision of loans, capital market instruments and other types of financial instruments to Russia-related persons.{{ FIELD }}A major Middle East petrochemicals company on EU sanctions with respect to Iran and Syria and potential exposure based on business transactions with Iranian and Syrian entities.{{ FIELD }}A significant Middle East sovereign wealth fund on the successful de-listing of one its associated companies from the EU sanctions list.{{ FIELD }}A major Asian oil and gas company in connection with the EU relaxation of sanctions on investments in the Iranian hydrocarbons sector and on Iranian oil exports under the Joint Comprehensive Plan of Action.{{ FIELD }}A significant aircraft manufacturer on export sales of aircraft and aircraft parts from certain EU countries to the Middle East region and South America.{{ FIELD }}An aerospace client in its UK voluntary self-disclosures due to potential violation of UK/EU export control rules. The representation included review of customer due-diligence policies and procedures as well as sales contracts for the purposes of export controls and sanctions compliance.{{ FIELD }}Sajid Ahmed is a Partner in the London office of King \u0026amp; Spalding.  He specialises in international arbitration and trade matters. \nSajid’s cases are typically high-value complex disputes, often dealing with political, commercial and/or social issues involving State owned entities and governments.  Sajid represents both claimants and respondents in arbitral proceedings under all the major arbitral rules and institutions including the ICC, LCIA, ICSID and UNCITRAL. While sector agnostic, Sajid is particularly well-known for handling disputes in energy, mining, life sciences, financial services, and media where he is listed as a “name to note”.  Although experienced across various geographies, Sajid is prominently known for his disputes work in India, Turkey and Central Asia. Correspondingly, Sajid's global clientele include multi-nationals and State/State entities in those regions.  As a recipient of a number of recognitions from legal directories and industry commentators over the years,  Sajid is described as having “indispensable leadership” (IBLJ (2022)) and as being “an excellent lawyer with good business acumen and understands client’s perspective and overall business context and comes out with pragmatic solutions” (Legal 500 UK, 2021).\nSajid also has notable experience in international trade matters including export controls and sanctions. He assists clients prepare disclosures of export control and economic sanctions laws violations and represents them in regulatory investigations. Sajid Ahmed Partner “Indispensable Leadership”  India Business Law Journal (2022) Recognized as “an excellent lawyer with good business acumen\" LEGAL 500, 2021 \"Understands client’s perspective and overall business context and comes out with pragmatic solutions\"  Legal 500, 2021 Recognized as “a name to note” LEGAL 500, 2021 Law Society of England and Wales Recent Representations – Arbitration MattersAn Asian Exploration \u0026amp; Production company in an ad hoc UNCITRAL arbitration against the Government of India with respect to cross-boundary gas migration issues. An Indian pharmaceuticals company in a LCIA arbitration in London against a major Canadian generics producer with respect to a breach of exclusivity provisions in a licence agreement. A significant oil \u0026amp; gas company in two ad hoc UNCITRAL arbitrations against an Asian sovereign state, one relating to the company’s right to cost recovery under a PSC and the other relating to gas pricing. The Republic of Turkey and Turkish state-owned entity BOTAS in an ICC arbitration in Paris against the Republic of Iraq in relation to a dispute concerning an intergovernmental pipeline agreement. A significant Turkish E\u0026amp;P company against the Republic of Kazakhstan in an ICSID arbitration brought under the Turkey–Kazakhstan bilateral investment treaty relating to a tax stabilization clause. An Indian electrical engineering company in an ICC arbitration in London against a UK company involving claims of defective products provided pursuant to a Supply Agreement. A multinational life sciences company against a US company in an ICC arbitration in London concerning a breach of a licence agreement with respect to the marketing of a biopharmaceutical product. A significant Asian company in an LCIA arbitration in London against a U.S. investment bank relating to breaches of a services agreement in connection with an M\u0026amp;A deal. A significant pharmaceutical company in an ICC arbitration proceeding in New York against a German company relating to breaches of a manufacturing and supply agreement. Recent Representations – Export Controls and Sanctions MattersA major financial institution on EU-Russia sanctions concerning the provision of loans, capital market instruments and other types of financial instruments to Russia-related persons. A major Middle East petrochemicals company on EU sanctions with respect to Iran and Syria and potential exposure based on business transactions with Iranian and Syrian entities. A significant Middle East sovereign wealth fund on the successful de-listing of one its associated companies from the EU sanctions list. A major Asian oil and gas company in connection with the EU relaxation of sanctions on investments in the Iranian hydrocarbons sector and on Iranian oil exports under the Joint Comprehensive Plan of Action. A significant aircraft manufacturer on export sales of aircraft and aircraft parts from certain EU countries to the Middle East region and South America. An aerospace client in its UK voluntary self-disclosures due to potential violation of UK/EU export control rules. The representation included review of customer due-diligence policies and procedures as well as sales contracts for the purposes of export controls and sanctions compliance.","searchable_name":"Sajid Ahmed","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":174,"capability_group_featured":null,"home_page_featured":null},{"id":446166,"version":1,"owner_type":"Person","owner_id":3202,"payload":{"bio":"\u003cp\u003eA partner in the firm\u0026rsquo;s Government Advocacy and Public Policy group, J.C. helps companies and trade associations navigate legal, political and regulatory issues commonly associated with doing business in Europe and the United States. He is recognized by clients for his strong, bipartisan relationships with Members of Congress, State Attorneys General, congressional staff and senior government officials across key regulatory and executive branch agencies. He is trusted for his ability to rapidly synthesize complex information and communicate its strategic implications to policymakers and senior institutional stakeholders as well as his candid evaluation of options and potential for success.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAs former counsel to the Senate Banking Committee, J.C has developed a deep expertise in financial services, fintech, and emerging technology policy. He has a proven track record of influencing federal legislation, regulatory frameworks, and agency rulemaking impacting digital assets, banking, payments, and technology platforms. J.C. regularly interfaces with financial regulators on a wide array of policy and institution-specific issues, and as co-chair of the firm\u0026rsquo;s State Attorneys General practice, delivers results on high-impact legal work at the intersection of law, policy and regulation.\u003c/p\u003e\n\u003cp\u003eJ.C. is skilled in developing and executing comprehensive advocacy strategies, shaping legislative language, and positioning clients to successfully navigate complex and evolving policy environments at the federal, state and international levels. As President of the Parliamentary Intelligence-Security Forum, he has briefed policymakers throughout Europe, Africa, Latin America, and the Indo-Pacific. JC also advises international clients seeking to invest, expand, or operate in the United States.\u003c/p\u003e\n\u003cp\u003ePresident George W. Bush appointed J.C. to a six-year term as U.S. representative to the World Bank\u0026rsquo;s International Centre for Settlement of Investment Disputes (ICSID). Mayor Muriel Bowser also appointed J.C. to the District of Columbia; Board of Elections, in which capacity he also served on the U.S. Election Assistance Commission Standards Board. He is currently chairman of the Board of Visitors of The Catholic University Columbus School of Law and President of the Parliamentary Intelligence-Security Forum, where he is a regular speaker on cryptocurrency, artificial intelligence and critical minerals.\u003c/p\u003e\n\u003cp\u003eEarlier in his career, J.C. established the Boggs Scholarship for Public Service at the University of Delaware in honor of his grandfather and namesake, former U.S. Congressman, Senator and Governor of Delaware, J. Caleb Boggs. He has also served on numerous corporate and non-profit boards, including Jobs for Delaware Graduates (Chairman); The Reserve Trust Company (Vice Chairman), Global Center for Social Entrepreneurship Network (Secretary), Republican National Lawyers Association (President), Kimball Union Academy (Chairman of the Committee on Trustees), and AAA Mid-Atlantic.\u003c/p\u003e\n\u003cp\u003eJ.C. enjoys open-water swimming and is member of U.S. Masters Swimming and the historic Serpentine Swimming Club situated in London's Hyde Park. He has competed in swimming events across all 50 states, ten Canadian provinces and around the world.\u003c/p\u003e","slug":"j-c-boggs","email":"jboggs@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":154},{"id":290}]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":1,"source":"capabilities"},{"id":699,"guid":"699.smart_tags","index":2,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":3,"source":"smartTags"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":5,"source":"smartTags"},{"id":687,"guid":"687.smart_tags","index":6,"source":"smartTags"},{"id":118,"guid":"118.capabilities","index":7,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":8,"source":"capabilities"},{"id":110,"guid":"110.capabilities","index":9,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":10,"source":"capabilities"},{"id":1568,"guid":"1568.smart_tags","index":11,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":12,"source":"capabilities"}],"is_active":true,"last_name":"Boggs","nick_name":"J.C.","clerkships":[{"name":"Law Clerk, Court of Chancery, Delaware","years_held":"1987-88"}],"first_name":"J.C.","title_rank":9999,"updated_by":202,"law_schools":[{"id":3010,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1987-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":"","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in the firm\u0026rsquo;s Government Advocacy and Public Policy group, J.C. helps companies and trade associations navigate legal, political and regulatory issues commonly associated with doing business in Europe and the United States. He is recognized by clients for his strong, bipartisan relationships with Members of Congress, State Attorneys General, congressional staff and senior government officials across key regulatory and executive branch agencies. He is trusted for his ability to rapidly synthesize complex information and communicate its strategic implications to policymakers and senior institutional stakeholders as well as his candid evaluation of options and potential for success.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAs former counsel to the Senate Banking Committee, J.C has developed a deep expertise in financial services, fintech, and emerging technology policy. He has a proven track record of influencing federal legislation, regulatory frameworks, and agency rulemaking impacting digital assets, banking, payments, and technology platforms. J.C. regularly interfaces with financial regulators on a wide array of policy and institution-specific issues, and as co-chair of the firm\u0026rsquo;s State Attorneys General practice, delivers results on high-impact legal work at the intersection of law, policy and regulation.\u003c/p\u003e\n\u003cp\u003eJ.C. is skilled in developing and executing comprehensive advocacy strategies, shaping legislative language, and positioning clients to successfully navigate complex and evolving policy environments at the federal, state and international levels. As President of the Parliamentary Intelligence-Security Forum, he has briefed policymakers throughout Europe, Africa, Latin America, and the Indo-Pacific. JC also advises international clients seeking to invest, expand, or operate in the United States.\u003c/p\u003e\n\u003cp\u003ePresident George W. Bush appointed J.C. to a six-year term as U.S. representative to the World Bank\u0026rsquo;s International Centre for Settlement of Investment Disputes (ICSID). Mayor Muriel Bowser also appointed J.C. to the District of Columbia; Board of Elections, in which capacity he also served on the U.S. Election Assistance Commission Standards Board. He is currently chairman of the Board of Visitors of The Catholic University Columbus School of Law and President of the Parliamentary Intelligence-Security Forum, where he is a regular speaker on cryptocurrency, artificial intelligence and critical minerals.\u003c/p\u003e\n\u003cp\u003eEarlier in his career, J.C. established the Boggs Scholarship for Public Service at the University of Delaware in honor of his grandfather and namesake, former U.S. Congressman, Senator and Governor of Delaware, J. Caleb Boggs. He has also served on numerous corporate and non-profit boards, including Jobs for Delaware Graduates (Chairman); The Reserve Trust Company (Vice Chairman), Global Center for Social Entrepreneurship Network (Secretary), Republican National Lawyers Association (President), Kimball Union Academy (Chairman of the Committee on Trustees), and AAA Mid-Atlantic.\u003c/p\u003e\n\u003cp\u003eJ.C. enjoys open-water swimming and is member of U.S. Masters Swimming and the historic Serpentine Swimming Club situated in London's Hyde Park. He has competed in swimming events across all 50 states, ten Canadian provinces and around the world.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9959}]},"capability_group_id":2},"created_at":"2026-02-25T20:07:32.000Z","updated_at":"2026-02-25T20:07:32.000Z","searchable_text":"Boggs{{ FIELD }}A partner in the firm’s Government Advocacy and Public Policy group, J.C. helps companies and trade associations navigate legal, political and regulatory issues commonly associated with doing business in Europe and the United States. He is recognized by clients for his strong, bipartisan relationships with Members of Congress, State Attorneys General, congressional staff and senior government officials across key regulatory and executive branch agencies. He is trusted for his ability to rapidly synthesize complex information and communicate its strategic implications to policymakers and senior institutional stakeholders as well as his candid evaluation of options and potential for success.\nAs former counsel to the Senate Banking Committee, J.C has developed a deep expertise in financial services, fintech, and emerging technology policy. He has a proven track record of influencing federal legislation, regulatory frameworks, and agency rulemaking impacting digital assets, banking, payments, and technology platforms. J.C. regularly interfaces with financial regulators on a wide array of policy and institution-specific issues, and as co-chair of the firm’s State Attorneys General practice, delivers results on high-impact legal work at the intersection of law, policy and regulation.\nJ.C. is skilled in developing and executing comprehensive advocacy strategies, shaping legislative language, and positioning clients to successfully navigate complex and evolving policy environments at the federal, state and international levels. As President of the Parliamentary Intelligence-Security Forum, he has briefed policymakers throughout Europe, Africa, Latin America, and the Indo-Pacific. JC also advises international clients seeking to invest, expand, or operate in the United States.\nPresident George W. Bush appointed J.C. to a six-year term as U.S. representative to the World Bank’s International Centre for Settlement of Investment Disputes (ICSID). Mayor Muriel Bowser also appointed J.C. to the District of Columbia; Board of Elections, in which capacity he also served on the U.S. Election Assistance Commission Standards Board. He is currently chairman of the Board of Visitors of The Catholic University Columbus School of Law and President of the Parliamentary Intelligence-Security Forum, where he is a regular speaker on cryptocurrency, artificial intelligence and critical minerals.\nEarlier in his career, J.C. established the Boggs Scholarship for Public Service at the University of Delaware in honor of his grandfather and namesake, former U.S. Congressman, Senator and Governor of Delaware, J. Caleb Boggs. He has also served on numerous corporate and non-profit boards, including Jobs for Delaware Graduates (Chairman); The Reserve Trust Company (Vice Chairman), Global Center for Social Entrepreneurship Network (Secretary), Republican National Lawyers Association (President), Kimball Union Academy (Chairman of the Committee on Trustees), and AAA Mid-Atlantic.\nJ.C. enjoys open-water swimming and is member of U.S. Masters Swimming and the historic Serpentine Swimming Club situated in London's Hyde Park. He has competed in swimming events across all 50 states, ten Canadian provinces and around the world. J.C. Boggs fintech Partner University of Richmond University of Richmond School of Law Columbus School of Law, Catholic University of America Columbus School of Law, Catholic University of America Georgetown University Georgetown University Law Center Supreme Court of the United States U.S. Court of Federal Claims U.S. District Court for the District of Delaware District of Columbia Delaware Law Clerk, Court of Chancery, Delaware","searchable_name":"J.C. Boggs","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":427703,"version":1,"owner_type":"Person","owner_id":1673,"payload":{"bio":"\u003cp\u003eBrian Bohnenkamp specializes in regulatory and compliance matters relating to drug, biotechnology and medical device companies. A partner in our FDA practice and a member of our Life Sciences group, Brian has extensive experience counseling manufacturers on fraud and abuse laws, industry codes of conduct, federal and state transparency laws and regulations, state and local gift bans, compliance program laws and sales representative licensing requirements, as well as government ethics restrictions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith a master\u0026rsquo;s degree in healthcare administration, Brian provides counsel to companies on a variety of laws and regulations administered and enforced by FDA, OIG, DOJ, and CMS, as well as by state attorneys general, boards of pharmacy, departments of health, and similar administrative and enforcement authorities. He regularly assists manufacturers in designing and implementing comprehensive compliance programs, and conducts risk assessments, audits and other reviews of compliance programs and business activities/operations.\u003c/p\u003e\n\u003cp\u003eBrian is regarded as a national expert on life sciences transparency laws and regulations, including the federal Physician Payments Sunshine Act (aka Open Payments) and similar state laws. He provides counsel to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of pharmaceutical, biotechnology and medical device manufacturers.\u003c/p\u003e","slug":"brian-bohnenkamp","email":"bbohnenkamp@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":25}]},"expertise":[{"id":103,"guid":"103.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":4,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":5,"source":"smartTags"},{"id":122,"guid":"122.capabilities","index":6,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":7,"source":"smartTags"},{"id":1193,"guid":"1193.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Bohnenkamp","nick_name":"Brian","clerkships":[],"first_name":"Brian","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"A.","name_suffix":"","recognitions":[{"title":"Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory ","detail":"Chambers USA, District of Columbia (2020-2022)"},{"title":"\"Brian's knowledge and experience are invaluable.\" ","detail":"Chambers USA (2022) "},{"title":"Next Generation Partner","detail":"Legal 500"},{"title":"Up and Coming for Pharmaceutical/Medical Products Regulatory","detail":"Chambers"},{"title":"Rising Star ","detail":"Washington, D.C. Super Lawyers, 2017-2020"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eBrian Bohnenkamp specializes in regulatory and compliance matters relating to drug, biotechnology and medical device companies. A partner in our FDA practice and a member of our Life Sciences group, Brian has extensive experience counseling manufacturers on fraud and abuse laws, industry codes of conduct, federal and state transparency laws and regulations, state and local gift bans, compliance program laws and sales representative licensing requirements, as well as government ethics restrictions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith a master\u0026rsquo;s degree in healthcare administration, Brian provides counsel to companies on a variety of laws and regulations administered and enforced by FDA, OIG, DOJ, and CMS, as well as by state attorneys general, boards of pharmacy, departments of health, and similar administrative and enforcement authorities. He regularly assists manufacturers in designing and implementing comprehensive compliance programs, and conducts risk assessments, audits and other reviews of compliance programs and business activities/operations.\u003c/p\u003e\n\u003cp\u003eBrian is regarded as a national expert on life sciences transparency laws and regulations, including the federal Physician Payments Sunshine Act (aka Open Payments) and similar state laws. He provides counsel to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of pharmaceutical, biotechnology and medical device manufacturers.\u003c/p\u003e","recognitions":[{"title":"Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory ","detail":"Chambers USA, District of Columbia (2020-2022)"},{"title":"\"Brian's knowledge and experience are invaluable.\" ","detail":"Chambers USA (2022) "},{"title":"Next Generation Partner","detail":"Legal 500"},{"title":"Up and Coming for Pharmaceutical/Medical Products Regulatory","detail":"Chambers"},{"title":"Rising Star ","detail":"Washington, D.C. Super Lawyers, 2017-2020"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":735}]},"capability_group_id":2},"created_at":"2025-05-26T05:03:56.000Z","updated_at":"2025-05-26T05:03:56.000Z","searchable_text":"Bohnenkamp{{ FIELD }}{:title=\u0026gt;\"Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory \", :detail=\u0026gt;\"Chambers USA, District of Columbia (2020-2022)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Brian's knowledge and experience are invaluable.\\\" \", :detail=\u0026gt;\"Chambers USA (2022) \"}{{ FIELD }}{:title=\u0026gt;\"Next Generation Partner\", :detail=\u0026gt;\"Legal 500\"}{{ FIELD }}{:title=\u0026gt;\"Up and Coming for Pharmaceutical/Medical Products Regulatory\", :detail=\u0026gt;\"Chambers\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star \", :detail=\u0026gt;\"Washington, D.C. Super Lawyers, 2017-2020\"}{{ FIELD }}Brian Bohnenkamp specializes in regulatory and compliance matters relating to drug, biotechnology and medical device companies. A partner in our FDA practice and a member of our Life Sciences group, Brian has extensive experience counseling manufacturers on fraud and abuse laws, industry codes of conduct, federal and state transparency laws and regulations, state and local gift bans, compliance program laws and sales representative licensing requirements, as well as government ethics restrictions.\nWith a master’s degree in healthcare administration, Brian provides counsel to companies on a variety of laws and regulations administered and enforced by FDA, OIG, DOJ, and CMS, as well as by state attorneys general, boards of pharmacy, departments of health, and similar administrative and enforcement authorities. He regularly assists manufacturers in designing and implementing comprehensive compliance programs, and conducts risk assessments, audits and other reviews of compliance programs and business activities/operations.\nBrian is regarded as a national expert on life sciences transparency laws and regulations, including the federal Physician Payments Sunshine Act (aka Open Payments) and similar state laws. He provides counsel to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of pharmaceutical, biotechnology and medical device manufacturers. Brian A Bohnenkamp Partner Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory  Chambers USA, District of Columbia (2020-2022) \"Brian's knowledge and experience are invaluable.\"  Chambers USA (2022)  Next Generation Partner Legal 500 Up and Coming for Pharmaceutical/Medical Products Regulatory Chambers Rising Star  Washington, D.C. Super Lawyers, 2017-2020 Indiana University Indiana University School of Law St. Louis University  St. Louis University  District of Columbia Illinois","searchable_name":"Brian A. Bohnenkamp","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":438577,"version":1,"owner_type":"Person","owner_id":3229,"payload":{"bio":"\u003cp\u003eJim Bowe focuses on the energy sector, including regulation of the pipeline, oil and gas, hydrogen/renewable fuels and electric power industries, and commercial matters relating to energy production, transportation, storage and use. Jim advises clients on energy and infrastructure project development and financing, energy and environmental regulatory compliance questions, clean energy incentive regimes and energy transactions. \u0026nbsp;He has handled energy matters in North America, South America and the Middle East.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJim represents both conventional and renewable energy project developers, owners, operators, investors and lenders, as well as energy shippers and end users. He advises clients in securing authorizations to build and expand energy production, transportation and storage facilities, and in rate and enforcement proceedings before federal, state and territorial regulators. Jim has also represented financial institutions and project developers in connection with the development and financing of U.S. and international energy projects, and in merger and acquisition matters involving energy assets and companies.\u003c/p\u003e\n\u003cp\u003eJim counsels clients on energy supply, transportation, storage, asset management and tolling agreement negotiations; permitting issues; energy company reorganizations; and transactions and financings involving natural gas, liquefied natural gas, petroleum, hydrogen and renewable fuels, conventional and renewable electric power generation, electric transmission, and district energy. Jim also assists energy sector clients in addressing environmental permitting and compliance issues (including climate change and Environmental Justice issues) and pipeline safety issues.\u003c/p\u003e\n\u003cp\u003eExperienced in a wide range of energy sector law, Jim is a frequent speaker, panelist and author. Jim heads King \u0026amp; Spalding\u0026rsquo;s Hydrogen Initiative, which serves as a clearinghouse for information relating to the evolution of hydrogen as a clean fuel, energy storage medium and renewable energy enabler and the firm\u0026rsquo;s work in this growing area.\u0026nbsp; Jim has been recognized for two decades as a leading practitioner in the oil \u0026amp; gas sector by publications such as Chambers Global, Chambers USA, Legal 500 and Best Lawyers.\u003c/p\u003e","slug":"james-bowe","email":"jbowe@kslaw.com","phone":"+1-202-744-7768","matters":["\u003cp\u003eRepresents\u0026nbsp;\u003cstrong\u003enatural gas pipeline companies, natural gas storage companies, midstream companies, LNG terminal developers, and pipeline shippers\u003c/strong\u003e\u0026nbsp;in a variety of rate, tariff, capacity allocation and export authorization proceedings before the U.S. Department of Energy, the Federal Energy Regulatory Commission, the U.S. Department of Transportation, the U.S. Department of the Interior and other U.S. regulators.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003edevelopers of conventional and renewable electric generation facilities, hydrogen hub and production facilities, renewable fuels production projects, district energy facilities and energy storage providers\u0026nbsp;\u003c/strong\u003eon permitting matters, concession arrangements, fuel supply and offtake contract negotiations, regulatory approvals and financing matters.\u003c/p\u003e","\u003cp\u003eRepresents\u0026nbsp;\u003cstrong\u003esponsors and offtakers in the development, permitting, expansion and financing of gas-fired, biomass fueled and wind electric generating facilities and hydrogen hubs in the U.S., Canada, Mexico and Brazil,\u003c/strong\u003e\u0026nbsp;including some of the largest wind generation projects developed to date in Texas; more than a dozen underground natural gas storage projects in the U.S.; numerous natural gas, petroleum and petrochemicals pipeline construction and expansion projects in the U.S. and Canada; several natural gas and oil production facility, gathering system, processing plant and pipeline construction and expansion projects in the U.S. and Canada; liquefied natural gas production, storage, import and export facilities in the U.S., Canada and Mexico; hydrogen production, storage and distribution facilities in the U.S. and Canada; and several expansions or conversions of energy pipeline facilities to ethane and other NGLs service.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003epotential investors\u003c/strong\u003e\u0026nbsp;in connection with the evaluation of pipeline, storage facility, electric generating facility, electric transmission facility, hydrogen and clean fuels production and storage projects for potential acquisition.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003easset owners, infrastructure funds, and master limited partnerships\u003c/strong\u003e\u0026nbsp;in sales and purchases of ownership interests in natural gas storage facilities, natural gas pipelines, oil and gas midstream companies, gas distribution companies, electric utilities, and conventional and renewable electric power generation facilities.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003enatural gas, oil, NGLs, hydrogen and CO2 pipeline and storage facility owners, prospective owners and operators\u003c/strong\u003e\u0026nbsp;on compliance with pipeline safety regulations administered by the U.S. Department of Transportation's Pipeline and Hazardous Materials Safety Administration.\u003c/p\u003e","\u003cp\u003eAdvised\u0026nbsp;\u003cstrong\u003ea\u003c/strong\u003e\u0026nbsp;\u003cstrong\u003egovernment agency and other stakeholders\u003c/strong\u003e\u0026nbsp;on the structuring of regulatory regimes to govern the development, operation and service offerings of district cooling facilities and the restructuring of the water/wastewater sectors in two jurisdictions in the Middle East.\u003c/p\u003e","\u003cp\u003eAdvised\u0026nbsp;\u003cstrong\u003eparticipants in Brazil\u0026rsquo;s independent power and natural gas sectors\u003c/strong\u003e\u0026nbsp;on commercial, project development and regulatory policy matters.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":35,"guid":"35.capabilities","index":0,"source":"capabilities"},{"id":33,"guid":"33.capabilities","index":1,"source":"capabilities"},{"id":78,"guid":"78.capabilities","index":2,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":3,"source":"capabilities"},{"id":22,"guid":"22.capabilities","index":4,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":5,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":6,"source":"capabilities"},{"id":75,"guid":"75.capabilities","index":7,"source":"capabilities"},{"id":984,"guid":"984.smart_tags","index":8,"source":"smartTags"},{"id":1114,"guid":"1114.smart_tags","index":9,"source":"smartTags"},{"id":1149,"guid":"1149.smart_tags","index":10,"source":"smartTags"},{"id":122,"guid":"122.capabilities","index":11,"source":"capabilities"},{"id":125,"guid":"125.capabilities","index":12,"source":"capabilities"},{"id":1219,"guid":"1219.smart_tags","index":13,"source":"smartTags"},{"id":1236,"guid":"1236.smart_tags","index":14,"source":"smartTags"},{"id":107,"guid":"107.capabilities","index":15,"source":"capabilities"},{"id":131,"guid":"131.capabilities","index":16,"source":"capabilities"},{"id":132,"guid":"132.capabilities","index":17,"source":"capabilities"},{"id":1488,"guid":"1488.smart_tags","index":18,"source":"smartTags"},{"id":1434,"guid":"1434.smart_tags","index":19,"source":"smartTags"}],"is_active":true,"last_name":"Bowe","nick_name":"Jim","clerkships":[],"first_name":"James","title_rank":9999,"updated_by":202,"law_schools":[{"id":1451,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1982-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"F.","name_suffix":"Jr.","recognitions":[{"title":"One of the U.S. Energy Bar’s leading lawyers","detail":"Chambers USA and Chambers Global, 2003–2025"},{"title":"Ranked in Nationwide, Energy: Oil \u0026 Gas (Regulatory \u0026 Litigation)","detail":"Chambers USA, 2017-2025"},{"title":"A Leading Lawyer in Energy: Regulatory","detail":"Legal 500 United States, 2016-2023"},{"title":"One of Washington, D.C.’s Super Lawyers in Energy \u0026 Natural Resources","detail":"Super Lawyers, 2014–2025"}],"linked_in_url":"https://www.linkedin.com/in/james-bowe-26a6515/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJim Bowe focuses on the energy sector, including regulation of the pipeline, oil and gas, hydrogen/renewable fuels and electric power industries, and commercial matters relating to energy production, transportation, storage and use. Jim advises clients on energy and infrastructure project development and financing, energy and environmental regulatory compliance questions, clean energy incentive regimes and energy transactions. \u0026nbsp;He has handled energy matters in North America, South America and the Middle East.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJim represents both conventional and renewable energy project developers, owners, operators, investors and lenders, as well as energy shippers and end users. He advises clients in securing authorizations to build and expand energy production, transportation and storage facilities, and in rate and enforcement proceedings before federal, state and territorial regulators. Jim has also represented financial institutions and project developers in connection with the development and financing of U.S. and international energy projects, and in merger and acquisition matters involving energy assets and companies.\u003c/p\u003e\n\u003cp\u003eJim counsels clients on energy supply, transportation, storage, asset management and tolling agreement negotiations; permitting issues; energy company reorganizations; and transactions and financings involving natural gas, liquefied natural gas, petroleum, hydrogen and renewable fuels, conventional and renewable electric power generation, electric transmission, and district energy. Jim also assists energy sector clients in addressing environmental permitting and compliance issues (including climate change and Environmental Justice issues) and pipeline safety issues.\u003c/p\u003e\n\u003cp\u003eExperienced in a wide range of energy sector law, Jim is a frequent speaker, panelist and author. Jim heads King \u0026amp; Spalding\u0026rsquo;s Hydrogen Initiative, which serves as a clearinghouse for information relating to the evolution of hydrogen as a clean fuel, energy storage medium and renewable energy enabler and the firm\u0026rsquo;s work in this growing area.\u0026nbsp; Jim has been recognized for two decades as a leading practitioner in the oil \u0026amp; gas sector by publications such as Chambers Global, Chambers USA, Legal 500 and Best Lawyers.\u003c/p\u003e","matters":["\u003cp\u003eRepresents\u0026nbsp;\u003cstrong\u003enatural gas pipeline companies, natural gas storage companies, midstream companies, LNG terminal developers, and pipeline shippers\u003c/strong\u003e\u0026nbsp;in a variety of rate, tariff, capacity allocation and export authorization proceedings before the U.S. Department of Energy, the Federal Energy Regulatory Commission, the U.S. Department of Transportation, the U.S. Department of the Interior and other U.S. regulators.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003edevelopers of conventional and renewable electric generation facilities, hydrogen hub and production facilities, renewable fuels production projects, district energy facilities and energy storage providers\u0026nbsp;\u003c/strong\u003eon permitting matters, concession arrangements, fuel supply and offtake contract negotiations, regulatory approvals and financing matters.\u003c/p\u003e","\u003cp\u003eRepresents\u0026nbsp;\u003cstrong\u003esponsors and offtakers in the development, permitting, expansion and financing of gas-fired, biomass fueled and wind electric generating facilities and hydrogen hubs in the U.S., Canada, Mexico and Brazil,\u003c/strong\u003e\u0026nbsp;including some of the largest wind generation projects developed to date in Texas; more than a dozen underground natural gas storage projects in the U.S.; numerous natural gas, petroleum and petrochemicals pipeline construction and expansion projects in the U.S. and Canada; several natural gas and oil production facility, gathering system, processing plant and pipeline construction and expansion projects in the U.S. and Canada; liquefied natural gas production, storage, import and export facilities in the U.S., Canada and Mexico; hydrogen production, storage and distribution facilities in the U.S. and Canada; and several expansions or conversions of energy pipeline facilities to ethane and other NGLs service.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003epotential investors\u003c/strong\u003e\u0026nbsp;in connection with the evaluation of pipeline, storage facility, electric generating facility, electric transmission facility, hydrogen and clean fuels production and storage projects for potential acquisition.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003easset owners, infrastructure funds, and master limited partnerships\u003c/strong\u003e\u0026nbsp;in sales and purchases of ownership interests in natural gas storage facilities, natural gas pipelines, oil and gas midstream companies, gas distribution companies, electric utilities, and conventional and renewable electric power generation facilities.\u003c/p\u003e","\u003cp\u003eAdvises\u0026nbsp;\u003cstrong\u003enatural gas, oil, NGLs, hydrogen and CO2 pipeline and storage facility owners, prospective owners and operators\u003c/strong\u003e\u0026nbsp;on compliance with pipeline safety regulations administered by the U.S. Department of Transportation's Pipeline and Hazardous Materials Safety Administration.\u003c/p\u003e","\u003cp\u003eAdvised\u0026nbsp;\u003cstrong\u003ea\u003c/strong\u003e\u0026nbsp;\u003cstrong\u003egovernment agency and other stakeholders\u003c/strong\u003e\u0026nbsp;on the structuring of regulatory regimes to govern the development, operation and service offerings of district cooling facilities and the restructuring of the water/wastewater sectors in two jurisdictions in the Middle East.\u003c/p\u003e","\u003cp\u003eAdvised\u0026nbsp;\u003cstrong\u003eparticipants in Brazil\u0026rsquo;s independent power and natural gas sectors\u003c/strong\u003e\u0026nbsp;on commercial, project development and regulatory policy matters.\u003c/p\u003e"],"recognitions":[{"title":"One of the U.S. Energy Bar’s leading lawyers","detail":"Chambers USA and Chambers Global, 2003–2025"},{"title":"Ranked in Nationwide, Energy: Oil \u0026 Gas (Regulatory \u0026 Litigation)","detail":"Chambers USA, 2017-2025"},{"title":"A Leading Lawyer in Energy: Regulatory","detail":"Legal 500 United States, 2016-2023"},{"title":"One of Washington, D.C.’s Super Lawyers in Energy \u0026 Natural Resources","detail":"Super Lawyers, 2014–2025"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":739}]},"capability_group_id":1},"created_at":"2025-09-30T16:09:09.000Z","updated_at":"2025-09-30T16:09:09.000Z","searchable_text":"Bowe{{ FIELD }}{:title=\u0026gt;\"One of the U.S. Energy Bar’s leading lawyers\", :detail=\u0026gt;\"Chambers USA and Chambers Global, 2003–2025\"}{{ FIELD }}{:title=\u0026gt;\"Ranked in Nationwide, Energy: Oil \u0026amp; Gas (Regulatory \u0026amp; Litigation)\", :detail=\u0026gt;\"Chambers USA, 2017-2025\"}{{ FIELD }}{:title=\u0026gt;\"A Leading Lawyer in Energy: Regulatory\", :detail=\u0026gt;\"Legal 500 United States, 2016-2023\"}{{ FIELD }}{:title=\u0026gt;\"One of Washington, D.C.’s Super Lawyers in Energy \u0026amp; Natural Resources\", :detail=\u0026gt;\"Super Lawyers, 2014–2025\"}{{ FIELD }}Represents natural gas pipeline companies, natural gas storage companies, midstream companies, LNG terminal developers, and pipeline shippers in a variety of rate, tariff, capacity allocation and export authorization proceedings before the U.S. Department of Energy, the Federal Energy Regulatory Commission, the U.S. Department of Transportation, the U.S. Department of the Interior and other U.S. regulators.{{ FIELD }}Advises developers of conventional and renewable electric generation facilities, hydrogen hub and production facilities, renewable fuels production projects, district energy facilities and energy storage providers on permitting matters, concession arrangements, fuel supply and offtake contract negotiations, regulatory approvals and financing matters.{{ FIELD }}Represents sponsors and offtakers in the development, permitting, expansion and financing of gas-fired, biomass fueled and wind electric generating facilities and hydrogen hubs in the U.S., Canada, Mexico and Brazil, including some of the largest wind generation projects developed to date in Texas; more than a dozen underground natural gas storage projects in the U.S.; numerous natural gas, petroleum and petrochemicals pipeline construction and expansion projects in the U.S. and Canada; several natural gas and oil production facility, gathering system, processing plant and pipeline construction and expansion projects in the U.S. and Canada; liquefied natural gas production, storage, import and export facilities in the U.S., Canada and Mexico; hydrogen production, storage and distribution facilities in the U.S. and Canada; and several expansions or conversions of energy pipeline facilities to ethane and other NGLs service.{{ FIELD }}Advises potential investors in connection with the evaluation of pipeline, storage facility, electric generating facility, electric transmission facility, hydrogen and clean fuels production and storage projects for potential acquisition.{{ FIELD }}Advises asset owners, infrastructure funds, and master limited partnerships in sales and purchases of ownership interests in natural gas storage facilities, natural gas pipelines, oil and gas midstream companies, gas distribution companies, electric utilities, and conventional and renewable electric power generation facilities.{{ FIELD }}Advises natural gas, oil, NGLs, hydrogen and CO2 pipeline and storage facility owners, prospective owners and operators on compliance with pipeline safety regulations administered by the U.S. Department of Transportation's Pipeline and Hazardous Materials Safety Administration.{{ FIELD }}Advised a government agency and other stakeholders on the structuring of regulatory regimes to govern the development, operation and service offerings of district cooling facilities and the restructuring of the water/wastewater sectors in two jurisdictions in the Middle East.{{ FIELD }}Advised participants in Brazil’s independent power and natural gas sectors on commercial, project development and regulatory policy matters.{{ FIELD }}Jim Bowe focuses on the energy sector, including regulation of the pipeline, oil and gas, hydrogen/renewable fuels and electric power industries, and commercial matters relating to energy production, transportation, storage and use. Jim advises clients on energy and infrastructure project development and financing, energy and environmental regulatory compliance questions, clean energy incentive regimes and energy transactions.  He has handled energy matters in North America, South America and the Middle East.\nJim represents both conventional and renewable energy project developers, owners, operators, investors and lenders, as well as energy shippers and end users. He advises clients in securing authorizations to build and expand energy production, transportation and storage facilities, and in rate and enforcement proceedings before federal, state and territorial regulators. Jim has also represented financial institutions and project developers in connection with the development and financing of U.S. and international energy projects, and in merger and acquisition matters involving energy assets and companies.\nJim counsels clients on energy supply, transportation, storage, asset management and tolling agreement negotiations; permitting issues; energy company reorganizations; and transactions and financings involving natural gas, liquefied natural gas, petroleum, hydrogen and renewable fuels, conventional and renewable electric power generation, electric transmission, and district energy. Jim also assists energy sector clients in addressing environmental permitting and compliance issues (including climate change and Environmental Justice issues) and pipeline safety issues.\nExperienced in a wide range of energy sector law, Jim is a frequent speaker, panelist and author. Jim heads King \u0026amp; Spalding’s Hydrogen Initiative, which serves as a clearinghouse for information relating to the evolution of hydrogen as a clean fuel, energy storage medium and renewable energy enabler and the firm’s work in this growing area.  Jim has been recognized for two decades as a leading practitioner in the oil \u0026amp; gas sector by publications such as Chambers Global, Chambers USA, Legal 500 and Best Lawyers. Partner One of the U.S. Energy Bar’s leading lawyers Chambers USA and Chambers Global, 2003–2025 Ranked in Nationwide, Energy: Oil \u0026amp; Gas (Regulatory \u0026amp; Litigation) Chambers USA, 2017-2025 A Leading Lawyer in Energy: Regulatory Legal 500 United States, 2016-2023 One of Washington, D.C.’s Super Lawyers in Energy \u0026amp; Natural Resources Super Lawyers, 2014–2025 Williams College  Northwestern University Northwestern Pritzker School of Law District of Columbia American Bar Association Energy Bar Association Represents natural gas pipeline companies, natural gas storage companies, midstream companies, LNG terminal developers, and pipeline shippers in a variety of rate, tariff, capacity allocation and export authorization proceedings before the U.S. Department of Energy, the Federal Energy Regulatory Commission, the U.S. Department of Transportation, the U.S. Department of the Interior and other U.S. regulators. Advises developers of conventional and renewable electric generation facilities, hydrogen hub and production facilities, renewable fuels production projects, district energy facilities and energy storage providers on permitting matters, concession arrangements, fuel supply and offtake contract negotiations, regulatory approvals and financing matters. Represents sponsors and offtakers in the development, permitting, expansion and financing of gas-fired, biomass fueled and wind electric generating facilities and hydrogen hubs in the U.S., Canada, Mexico and Brazil, including some of the largest wind generation projects developed to date in Texas; more than a dozen underground natural gas storage projects in the U.S.; numerous natural gas, petroleum and petrochemicals pipeline construction and expansion projects in the U.S. and Canada; several natural gas and oil production facility, gathering system, processing plant and pipeline construction and expansion projects in the U.S. and Canada; liquefied natural gas production, storage, import and export facilities in the U.S., Canada and Mexico; hydrogen production, storage and distribution facilities in the U.S. and Canada; and several expansions or conversions of energy pipeline facilities to ethane and other NGLs service. Advises potential investors in connection with the evaluation of pipeline, storage facility, electric generating facility, electric transmission facility, hydrogen and clean fuels production and storage projects for potential acquisition. Advises asset owners, infrastructure funds, and master limited partnerships in sales and purchases of ownership interests in natural gas storage facilities, natural gas pipelines, oil and gas midstream companies, gas distribution companies, electric utilities, and conventional and renewable electric power generation facilities. Advises natural gas, oil, NGLs, hydrogen and CO2 pipeline and storage facility owners, prospective owners and operators on compliance with pipeline safety regulations administered by the U.S. Department of Transportation's Pipeline and Hazardous Materials Safety Administration. Advised a government agency and other stakeholders on the structuring of regulatory regimes to govern the development, operation and service offerings of district cooling facilities and the restructuring of the water/wastewater sectors in two jurisdictions in the Middle East. Advised participants in Brazil’s independent power and natural gas sectors on commercial, project development and regulatory policy matters.","searchable_name":"James F. Bowe, Jr. (Jim)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426829,"version":1,"owner_type":"Person","owner_id":5863,"payload":{"bio":"\u003cp\u003eChristine M. Carletta is a\u0026nbsp;partner in the Washington, D.C. office of King \u0026amp; Spalding. As\u0026nbsp;a member of the firm\u0026rsquo;s Appellate, Constitutional, and Administrative Law practice group, Christine develops creative litigation strategies to best serve her clients\u0026rsquo; objectives through all phases of litigation and appeal. Christine\u0026rsquo;s extensive experience covers a broad range of subjects including\u0026nbsp;Medicare and Medicaid regulation, Food and Drug Administration regulation, the False Claims Act, fraud and abuse matters, state and federal privacy laws, securities regulations, contract disputes, consumer protection claims, and\u0026nbsp;class actions.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Christine served as a law clerk to the Honorable Chad A Readler, United States Court of Appeals for the Sixth Circuit and the Honorable James C. Mahan, United States District Court for the District of Nevada. She received her J.D. from Vanderbilt Law School, where she served as Editor-in-Chief of\u0026nbsp;the Vanderbilt Journal of Entertainment and Technology Law.\u0026nbsp;\u0026nbsp;\u003c/p\u003e","slug":"christine-carletta","email":"ccarletta@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":1,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":2,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":3,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":4,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":5,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":6,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":7,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":8,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":9,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":10,"source":"smartTags"},{"id":761,"guid":"761.smart_tags","index":11,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Carletta","nick_name":"Christine","clerkships":[{"name":"Law Clerk, The Honorable Chad A. Readler, U.S. Court of Appeals for the Sixth Circuit","years_held":"2019 - 2020"},{"name":"Law Clerk, The Honorable James C. Mahan, U.S. District Court for the District of Nevada","years_held":"2015 - 2016"}],"first_name":"Christine","title_rank":9999,"updated_by":32,"law_schools":[{"id":2442,"meta":{"degree":"Juris Doctor","honors":"","is_law_school":"1","graduation_date":"2015-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eChristine M. Carletta is a\u0026nbsp;partner in the Washington, D.C. office of King \u0026amp; Spalding. As\u0026nbsp;a member of the firm\u0026rsquo;s Appellate, Constitutional, and Administrative Law practice group, Christine develops creative litigation strategies to best serve her clients\u0026rsquo; objectives through all phases of litigation and appeal. Christine\u0026rsquo;s extensive experience covers a broad range of subjects including\u0026nbsp;Medicare and Medicaid regulation, Food and Drug Administration regulation, the False Claims Act, fraud and abuse matters, state and federal privacy laws, securities regulations, contract disputes, consumer protection claims, and\u0026nbsp;class actions.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Christine served as a law clerk to the Honorable Chad A Readler, United States Court of Appeals for the Sixth Circuit and the Honorable James C. Mahan, United States District Court for the District of Nevada. She received her J.D. from Vanderbilt Law School, where she served as Editor-in-Chief of\u0026nbsp;the Vanderbilt Journal of Entertainment and Technology Law.\u0026nbsp;\u0026nbsp;\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9711}]},"capability_group_id":3},"created_at":"2025-05-26T04:57:14.000Z","updated_at":"2025-05-26T04:57:14.000Z","searchable_text":"Carletta{{ FIELD }}Christine M. Carletta is a partner in the Washington, D.C. office of King \u0026amp; Spalding. As a member of the firm’s Appellate, Constitutional, and Administrative Law practice group, Christine develops creative litigation strategies to best serve her clients’ objectives through all phases of litigation and appeal. Christine’s extensive experience covers a broad range of subjects including Medicare and Medicaid regulation, Food and Drug Administration regulation, the False Claims Act, fraud and abuse matters, state and federal privacy laws, securities regulations, contract disputes, consumer protection claims, and class actions. \nPrior to joining King \u0026amp; Spalding, Christine served as a law clerk to the Honorable Chad A Readler, United States Court of Appeals for the Sixth Circuit and the Honorable James C. Mahan, United States District Court for the District of Nevada. She received her J.D. from Vanderbilt Law School, where she served as Editor-in-Chief of the Vanderbilt Journal of Entertainment and Technology Law.   Partner Bowdoin College  Vanderbilt University Vanderbilt University School of Law U.S. Court of Appeals for the Second Circuit U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Sixth Circuit U.S. Court of Appeals for the Seventh Circuit U.S. Court of Appeals for the Tenth Circuit U.S. Court of Appeals for the D.C. Circuit U.S. District Court for the Eastern District of New York U.S. District Court for the Northern District of New York U.S. District Court for the Southern District of New York U.S. District Court for the Northern District of Illinois District of Columbia New York Law Clerk, The Honorable Chad A. Readler, U.S. Court of Appeals for the Sixth Circuit Law Clerk, The Honorable James C. Mahan, U.S. District Court for the District of Nevada","searchable_name":"Christine Carletta","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":32,"capability_group_featured":null,"home_page_featured":null},{"id":437180,"version":1,"owner_type":"Person","owner_id":2749,"payload":{"bio":"\u003cp\u003eDaniel Crosby specializes in international trade, investment and matters related to public international law. A partner in our International Trade practice and the manager of our Geneva office, Daniel helps sovereign and business clients to achieve practical economic objectives around the world by applying and negotiating international agreements.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDaniel represents major U.S. and European multinational corporations in a variety of trade and investment negotiations, and on the application of treaty-based rules to improve global market access for goods, services and e-commerce. He also advises clients regarding national trade remedy proceedings and World Trade Organization (WTO) disputes.\u003c/p\u003e\n\u003cp\u003eMuch of Daniel\u0026rsquo;s client work centers on energy issues, from natural resource production to energy services and trade in petrochemicals. He has particular experience in the Middle East, Russia and the states of the former Soviet Union. Daniel also has broad experience in assisting industries with international and national regulations concerning health, environmental and labor issues.\u003c/p\u003e\n\u003cp\u003eFluent in English, Russian, Hungarian and French, Daniel enjoys teaching, speaking and writing on international trade and investment issues. He also provides technical assistance and \u003cem data-redactor-tag=\"em\"\u003epro bono\u003c/em\u003e legal services to Least Developed Countries and to countries negotiating accession to the WTO or implementing WTO obligations.\u003c/p\u003e\n\u003cp\u003eDaniel is listed as a leading practitioner in international trade by \u003cem data-redactor-tag=\"em\"\u003eChambers Global,\u003c/em\u003e \u003cem data-redactor-tag=\"em\"\u003eChambers Europe, Chambers Switzerland, Who\u0026rsquo;s Who Legal,\u003c/em\u003e the \u003cem data-redactor-tag=\"em\"\u003eInternational Trade Expert Guide\u003c/em\u003e and \u003cem data-redactor-tag=\"em\"\u003eBest Lawyers/Switzerland.\u003c/em\u003e\u003c/p\u003e","slug":"daniel-crosby","email":"dcrosby@kslaw.com","phone":"+41 78 863 7403","matters":null,"taggings":{"tags":[],"meta_tags":[{"id":8}]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":25,"guid":"25.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":120,"guid":"120.capabilities","index":3,"source":"capabilities"},{"id":579,"guid":"579.smart_tags","index":4,"source":"smartTags"},{"id":1689,"guid":"1689.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"Crosby","nick_name":"Daniel","clerkships":[],"first_name":"Daniel","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Band 3, International Trade/WTO","detail":"Chambers Global, Europewide (2009-2022)"},{"title":"\"Understands business realities and doesn't stick to providing unusable legal analysis.\"","detail":"Chambers Global (2022)"},{"title":"\"Helps the client think of alternative strategies to solve issues.\"","detail":"Chambers Global (2022)"}],"linked_in_url":null,"seodescription":null,"primary_title_id":51,"translated_fields":{"en":{"bio":"\u003cp\u003eDaniel Crosby specializes in international trade, investment and matters related to public international law. A partner in our International Trade practice and the manager of our Geneva office, Daniel helps sovereign and business clients to achieve practical economic objectives around the world by applying and negotiating international agreements.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDaniel represents major U.S. and European multinational corporations in a variety of trade and investment negotiations, and on the application of treaty-based rules to improve global market access for goods, services and e-commerce. He also advises clients regarding national trade remedy proceedings and World Trade Organization (WTO) disputes.\u003c/p\u003e\n\u003cp\u003eMuch of Daniel\u0026rsquo;s client work centers on energy issues, from natural resource production to energy services and trade in petrochemicals. He has particular experience in the Middle East, Russia and the states of the former Soviet Union. Daniel also has broad experience in assisting industries with international and national regulations concerning health, environmental and labor issues.\u003c/p\u003e\n\u003cp\u003eFluent in English, Russian, Hungarian and French, Daniel enjoys teaching, speaking and writing on international trade and investment issues. He also provides technical assistance and \u003cem data-redactor-tag=\"em\"\u003epro bono\u003c/em\u003e legal services to Least Developed Countries and to countries negotiating accession to the WTO or implementing WTO obligations.\u003c/p\u003e\n\u003cp\u003eDaniel is listed as a leading practitioner in international trade by \u003cem data-redactor-tag=\"em\"\u003eChambers Global,\u003c/em\u003e \u003cem data-redactor-tag=\"em\"\u003eChambers Europe, Chambers Switzerland, Who\u0026rsquo;s Who Legal,\u003c/em\u003e the \u003cem data-redactor-tag=\"em\"\u003eInternational Trade Expert Guide\u003c/em\u003e and \u003cem data-redactor-tag=\"em\"\u003eBest Lawyers/Switzerland.\u003c/em\u003e\u003c/p\u003e","recognitions":[{"title":"Band 3, International Trade/WTO","detail":"Chambers Global, Europewide (2009-2022)"},{"title":"\"Understands business realities and doesn't stick to providing unusable legal analysis.\"","detail":"Chambers Global (2022)"},{"title":"\"Helps the client think of alternative strategies to solve issues.\"","detail":"Chambers Global (2022)"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6625}]},"capability_group_id":2},"created_at":"2025-09-15T16:54:26.000Z","updated_at":"2025-09-15T16:54:26.000Z","searchable_text":"Crosby{{ FIELD }}{:title=\u0026gt;\"Band 3, International Trade/WTO\", :detail=\u0026gt;\"Chambers Global, Europewide (2009-2022)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Understands business realities and doesn't stick to providing unusable legal analysis.\\\"\", :detail=\u0026gt;\"Chambers Global (2022)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Helps the client think of alternative strategies to solve issues.\\\"\", :detail=\u0026gt;\"Chambers Global (2022)\"}{{ FIELD }}Daniel Crosby specializes in international trade, investment and matters related to public international law. A partner in our International Trade practice and the manager of our Geneva office, Daniel helps sovereign and business clients to achieve practical economic objectives around the world by applying and negotiating international agreements.\nDaniel represents major U.S. and European multinational corporations in a variety of trade and investment negotiations, and on the application of treaty-based rules to improve global market access for goods, services and e-commerce. He also advises clients regarding national trade remedy proceedings and World Trade Organization (WTO) disputes.\nMuch of Daniel’s client work centers on energy issues, from natural resource production to energy services and trade in petrochemicals. He has particular experience in the Middle East, Russia and the states of the former Soviet Union. Daniel also has broad experience in assisting industries with international and national regulations concerning health, environmental and labor issues.\nFluent in English, Russian, Hungarian and French, Daniel enjoys teaching, speaking and writing on international trade and investment issues. He also provides technical assistance and pro bono legal services to Least Developed Countries and to countries negotiating accession to the WTO or implementing WTO obligations.\nDaniel is listed as a leading practitioner in international trade by Chambers Global, Chambers Europe, Chambers Switzerland, Who’s Who Legal, the International Trade Expert Guide and Best Lawyers/Switzerland. Daniel C Crosby Partner Band 3, International Trade/WTO Chambers Global, Europewide (2009-2022) \"Understands business realities and doesn't stick to providing unusable legal analysis.\" Chambers Global (2022) \"Helps the client think of alternative strategies to solve issues.\" Chambers Global (2022) Union College Albany Law School Leningrad/St. Petersburg State University  College of Ripon and York St. John  American University, Washington College of Law  District of Columbia Massachusetts New York American Bar Association International Bar Association","searchable_name":"Daniel Crosby","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":444001,"version":1,"owner_type":"Person","owner_id":7205,"payload":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","slug":"robert-deconti","email":"rdeconti@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"DeConti","nick_name":"Rob","clerkships":[],"first_name":"Robert","title_rank":9999,"updated_by":202,"law_schools":[{"id":3042,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1999-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}],"linked_in_url":"https://www.linkedin.com/in/robertdeconti","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12841}]},"capability_group_id":2},"created_at":"2025-12-05T05:02:32.000Z","updated_at":"2025-12-05T05:02:32.000Z","searchable_text":"DeConti{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Distinguished Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Meritorious Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Award for Fighting Fraud, Waste, and Abuse\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"President’s Council on Integrity and Efficiency Award for Excellence\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Office of Inspector General Cooperative Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Exceptional Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}Rob DeConti is a partner in King \u0026amp; Spalding’s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG’s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government’s enforcement and compliance priorities. \nWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government’s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG’s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government’s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG’s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\nBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG’s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG’s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide. \nPrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\nIn 2007, Rob served as a Special Trial Attorney in DOJ’s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel’s office at a managed care organization. Partner HHS Secretary’s Award for Distinguished Service  HHS Secretary’s Award for Meritorious Service  Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)  Inspector General’s Award for Fighting Fraud, Waste, and Abuse  President’s Council on Integrity and Efficiency Award for Excellence  Office of Inspector General Cooperative Achievement Award (multiple awards)  Inspector General’s Exceptional Achievement Award (multiple awards)  University of Virginia  American University Washington College of Law American University Washington College of Law District of Columbia Virginia Virginia State Bar American Health Law Association Government Attorney-at-Large, American Bar Association Health Law Section Council, 2022-2025 Government Liaison to the Health Care Compliance Association, Board of Directors, 2008-2012","searchable_name":"Robert K. DeConti (Rob)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":435271,"version":1,"owner_type":"Person","owner_id":1973,"payload":{"bio":"\u003cp\u003eDan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs\u0026nbsp;our Government Advocacy and Congressional Investigations practices perennially recognized by \u003cem\u003eChambers USA\u003c/em\u003e: \u0026ldquo;King \u0026amp; Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area.\u0026rdquo; Dan is ranked Band 1 for Congressional Investigations by \u003cem\u003eChambers USA \u003c/em\u003eand Tier 1 \u003cem\u003eLegal 500 US\u003c/em\u003e.\u0026nbsp; He\u0026nbsp;has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.\u003c/p\u003e\n\u003cp\u003eBefore joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, then Chairman of the Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.\u003c/p\u003e\n\u003cp\u003eDan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations.\u003c/p\u003e","slug":"daniel-donovan","email":"ddonovan@kslaw.com","phone":null,"matters":["\u003cp\u003eExperience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others.\u003c/p\u003e","\u003cp\u003eProviding advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in connection with congressional and state attorneys general drug pricing investigations.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;on healthcare policy and legislative issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major university\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical company\u003c/strong\u003e\u0026nbsp;in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea global financial institution\u003c/strong\u003e\u0026nbsp;in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea Big Four accounting firm\u003c/strong\u003e\u0026nbsp;in a Senate Finance Committee investigation of a University\u0026rsquo;s handling of federal funds.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act enactment and implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emedical device companies\u003c/strong\u003e\u0026nbsp;in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea leading clean energy technology company\u003c/strong\u003e\u0026nbsp;in connection with a Senate investigation into Department of Energy grant program.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major oil company\u003c/strong\u003e\u0026nbsp;in connection with congressional investigations.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea health insurer\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea coalition of food product companies\u003c/strong\u003e\u0026nbsp;in connection with congressional inquiries relating to food safety and regulatory issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea medical society\u003c/strong\u003e\u0026nbsp;in connection with Senate committee investigations in payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented individuals in connection with House and Senate committee inquiries and ethics investigations.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3464}]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":2,"source":"smartTags"},{"id":111,"guid":"111.capabilities","index":3,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":4,"source":"smartTags"},{"id":106,"guid":"106.capabilities","index":5,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":6,"source":"capabilities"},{"id":71,"guid":"71.capabilities","index":7,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":10,"source":"smartTags"},{"id":761,"guid":"761.smart_tags","index":11,"source":"smartTags"},{"id":17,"guid":"17.capabilities","index":12,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":13,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":14,"source":"capabilities"},{"id":128,"guid":"128.capabilities","index":15,"source":"capabilities"},{"id":1261,"guid":"1261.smart_tags","index":16,"source":"smartTags"},{"id":1270,"guid":"1270.smart_tags","index":17,"source":"smartTags"}],"is_active":true,"last_name":"Donovan","nick_name":"Dan","clerkships":[],"first_name":"Daniel","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"F.","name_suffix":"","recognitions":[{"title":"Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide","detail":"Chambers USA, 2021-2024"},{"title":"“[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.”","detail":"Chambers USA"},{"title":"Tier 1 Government Relations: Congressional Investigations","detail":"Legal 500 US, 2024"},{"title":"“Life Sciences Star” White-Collar/Govt. Investigations","detail":"LMG Life Sciences, 2024"},{"title":"GIR 100","detail":"Global Investigations Review, 2024"},{"title":"Tier 1 for Government Relations Practice","detail":"Best Lawyers, 2024"},{"title":"“[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.”","detail":"Chambers USA"},{"title":"“King \u0026 Spalding is best known for its impressive congressional investigations practice.”","detail":"Chambers USA, 2008-2024"},{"title":"“Daniel is an expert in Congressional investigations and is always able to keep a calm head”","detail":"Chambers USA, 2021-2024"},{"title":"“Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.”","detail":"Chambers USA"},{"title":"“[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan”","detail":"Legal 500 US"},{"title":"King \u0026 Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact”","detail":"Legal 500 US"},{"title":"Nationwide Government Relations Practice Ranking","detail":"Chambers USA 2008-2024"},{"title":"Leading Government Relations Lawyer","detail":"Legal 500 US, 2020-2024"},{"title":"Crisis Management and Government Oversight Practice Award","detail":"National Law Journal 2021"},{"title":"“Law Firm of the Year” for Government Relations","detail":"US News \u0026 World Report"}],"linked_in_url":"https://www.linkedin.com/in/dan-donovan-214322a/","seodescription":"Dan Donovan specializes in congressional, state attorneys general and parallel government investigations. Read more about him.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs\u0026nbsp;our Government Advocacy and Congressional Investigations practices perennially recognized by \u003cem\u003eChambers USA\u003c/em\u003e: \u0026ldquo;King \u0026amp; Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area.\u0026rdquo; Dan is ranked Band 1 for Congressional Investigations by \u003cem\u003eChambers USA \u003c/em\u003eand Tier 1 \u003cem\u003eLegal 500 US\u003c/em\u003e.\u0026nbsp; He\u0026nbsp;has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.\u003c/p\u003e\n\u003cp\u003eBefore joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, then Chairman of the Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.\u003c/p\u003e\n\u003cp\u003eDan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations.\u003c/p\u003e","matters":["\u003cp\u003eExperience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others.\u003c/p\u003e","\u003cp\u003eProviding advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in connection with congressional and state attorneys general drug pricing investigations.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;on healthcare policy and legislative issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major university\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical company\u003c/strong\u003e\u0026nbsp;in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea global financial institution\u003c/strong\u003e\u0026nbsp;in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea Big Four accounting firm\u003c/strong\u003e\u0026nbsp;in a Senate Finance Committee investigation of a University\u0026rsquo;s handling of federal funds.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act enactment and implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emedical device companies\u003c/strong\u003e\u0026nbsp;in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea leading clean energy technology company\u003c/strong\u003e\u0026nbsp;in connection with a Senate investigation into Department of Energy grant program.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major oil company\u003c/strong\u003e\u0026nbsp;in connection with congressional investigations.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea health insurer\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea coalition of food product companies\u003c/strong\u003e\u0026nbsp;in connection with congressional inquiries relating to food safety and regulatory issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea medical society\u003c/strong\u003e\u0026nbsp;in connection with Senate committee investigations in payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented individuals in connection with House and Senate committee inquiries and ethics investigations.\u003c/p\u003e"],"recognitions":[{"title":"Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide","detail":"Chambers USA, 2021-2024"},{"title":"“[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.”","detail":"Chambers USA"},{"title":"Tier 1 Government Relations: Congressional Investigations","detail":"Legal 500 US, 2024"},{"title":"“Life Sciences Star” White-Collar/Govt. Investigations","detail":"LMG Life Sciences, 2024"},{"title":"GIR 100","detail":"Global Investigations Review, 2024"},{"title":"Tier 1 for Government Relations Practice","detail":"Best Lawyers, 2024"},{"title":"“[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.”","detail":"Chambers USA"},{"title":"“King \u0026 Spalding is best known for its impressive congressional investigations practice.”","detail":"Chambers USA, 2008-2024"},{"title":"“Daniel is an expert in Congressional investigations and is always able to keep a calm head”","detail":"Chambers USA, 2021-2024"},{"title":"“Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.”","detail":"Chambers USA"},{"title":"“[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan”","detail":"Legal 500 US"},{"title":"King \u0026 Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact”","detail":"Legal 500 US"},{"title":"Nationwide Government Relations Practice Ranking","detail":"Chambers USA 2008-2024"},{"title":"Leading Government Relations Lawyer","detail":"Legal 500 US, 2020-2024"},{"title":"Crisis Management and Government Oversight Practice Award","detail":"National Law Journal 2021"},{"title":"“Law Firm of the Year” for Government Relations","detail":"US News \u0026 World Report"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9964}]},"capability_group_id":2},"created_at":"2025-08-14T15:45:04.000Z","updated_at":"2025-08-14T15:45:04.000Z","searchable_text":"Donovan{{ FIELD }}{:title=\u0026gt;\"Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide\", :detail=\u0026gt;\"Chambers USA, 2021-2024\"}{{ FIELD }}{:title=\u0026gt;\"“[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Tier 1 Government Relations: Congressional Investigations\", :detail=\u0026gt;\"Legal 500 US, 2024\"}{{ FIELD }}{:title=\u0026gt;\"“Life Sciences Star” White-Collar/Govt. Investigations\", :detail=\u0026gt;\"LMG Life Sciences, 2024\"}{{ FIELD }}{:title=\u0026gt;\"GIR 100\", :detail=\u0026gt;\"Global Investigations Review, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Tier 1 for Government Relations Practice\", :detail=\u0026gt;\"Best Lawyers, 2024\"}{{ FIELD }}{:title=\u0026gt;\"“[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"“King \u0026amp; Spalding is best known for its impressive congressional investigations practice.”\", :detail=\u0026gt;\"Chambers USA, 2008-2024\"}{{ FIELD }}{:title=\u0026gt;\"“Daniel is an expert in Congressional investigations and is always able to keep a calm head”\", :detail=\u0026gt;\"Chambers USA, 2021-2024\"}{{ FIELD }}{:title=\u0026gt;\"“Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"“[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan”\", :detail=\u0026gt;\"Legal 500 US\"}{{ FIELD }}{:title=\u0026gt;\"King \u0026amp; Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact”\", :detail=\u0026gt;\"Legal 500 US\"}{{ FIELD }}{:title=\u0026gt;\"Nationwide Government Relations Practice Ranking\", :detail=\u0026gt;\"Chambers USA 2008-2024\"}{{ FIELD }}{:title=\u0026gt;\"Leading Government Relations Lawyer\", :detail=\u0026gt;\"Legal 500 US, 2020-2024\"}{{ FIELD }}{:title=\u0026gt;\"Crisis Management and Government Oversight Practice Award\", :detail=\u0026gt;\"National Law Journal 2021\"}{{ FIELD }}{:title=\u0026gt;\"“Law Firm of the Year” for Government Relations\", :detail=\u0026gt;\"US News \u0026amp; World Report\"}{{ FIELD }}Experience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others.{{ FIELD }}Providing advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others.{{ FIELD }}Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.{{ FIELD }}Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations.{{ FIELD }}Representing a variety of clients on healthcare policy and legislative issues.{{ FIELD }}Represented a major university and pharmaceutical company in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.{{ FIELD }}Represented a global financial institution in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.{{ FIELD }}Represented a Big Four accounting firm in a Senate Finance Committee investigation of a University’s handling of federal funds.{{ FIELD }}Represented multiple pharmaceutical companies in House and Senate investigations related to Affordable Care Act enactment and implementation.{{ FIELD }}Represented medical device companies in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.{{ FIELD }}Represented a leading clean energy technology company in connection with a Senate investigation into Department of Energy grant program.{{ FIELD }}Represented a major oil company in connection with congressional investigations.{{ FIELD }}Represented a health insurer in House and Senate investigations related to Affordable Care Act implementation.{{ FIELD }}Represented a coalition of food product companies in connection with congressional inquiries relating to food safety and regulatory issues.{{ FIELD }}Represented a medical society in connection with Senate committee investigations in payments to physicians.{{ FIELD }}Represented individuals in connection with House and Senate committee inquiries and ethics investigations.{{ FIELD }}Dan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs our Government Advocacy and Congressional Investigations practices perennially recognized by Chambers USA: “King \u0026amp; Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area.” Dan is ranked Band 1 for Congressional Investigations by Chambers USA and Tier 1 Legal 500 US.  He has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.\nDan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.\nBefore joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, then Chairman of the Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.\nDan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations. Daniel Donovan lawyer Partner Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide Chambers USA, 2021-2024 “[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.” Chambers USA Tier 1 Government Relations: Congressional Investigations Legal 500 US, 2024 “Life Sciences Star” White-Collar/Govt. Investigations LMG Life Sciences, 2024 GIR 100 Global Investigations Review, 2024 Tier 1 for Government Relations Practice Best Lawyers, 2024 “[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.” Chambers USA “King \u0026amp; Spalding is best known for its impressive congressional investigations practice.” Chambers USA, 2008-2024 “Daniel is an expert in Congressional investigations and is always able to keep a calm head” Chambers USA, 2021-2024 “Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.” Chambers USA “[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan” Legal 500 US King \u0026amp; Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact” Legal 500 US Nationwide Government Relations Practice Ranking Chambers USA 2008-2024 Leading Government Relations Lawyer Legal 500 US, 2020-2024 Crisis Management and Government Oversight Practice Award National Law Journal 2021 “Law Firm of the Year” for Government Relations US News \u0026amp; World Report University of Rochester  American University Washington College of Law District of Columbia Maryland Experience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others. Providing advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others. Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest. Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations. Representing a variety of clients on healthcare policy and legislative issues. Represented a major university and pharmaceutical company in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research. Represented a global financial institution in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters. Represented a Big Four accounting firm in a Senate Finance Committee investigation of a University’s handling of federal funds. Represented multiple pharmaceutical companies in House and Senate investigations related to Affordable Care Act enactment and implementation. Represented medical device companies in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians. Represented a leading clean energy technology company in connection with a Senate investigation into Department of Energy grant program. Represented a major oil company in connection with congressional investigations. Represented a health insurer in House and Senate investigations related to Affordable Care Act implementation. Represented a coalition of food product companies in connection with congressional inquiries relating to food safety and regulatory issues. Represented a medical society in connection with Senate committee investigations in payments to physicians. Represented individuals in connection with House and Senate committee inquiries and ethics investigations.","searchable_name":"Daniel F. Donovan (Dan)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":431883,"version":1,"owner_type":"Person","owner_id":3969,"payload":{"bio":"\u003cp\u003eA partner in our FDA and Life Sciences practice, Lisa has almost 25\u0026nbsp;years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco). \u0026nbsp;She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner\u0026rsquo;s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency\u0026rsquo;s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\u003c/p\u003e\n\u003cp\u003eLisa is a frequent author and speaker on topics including:\u0026nbsp; digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women\u0026rsquo;s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her \u0026ldquo;unending enthusiasm to take on client\u0026rsquo;s causes as her own.\"\u003c/p\u003e","slug":"lisa-dwyer","email":"ldwyer@kslaw.com","phone":null,"matters":["\u003cp\u003eFocus on Digital Health/Telehealth\u003c/p\u003e","\u003cp\u003eFocus on In Vitro Diagnostic Tests and Laboratory Developed Tests\u003c/p\u003e","\u003cp\u003eFDA/FTC regulation of advertising and promotion\u003c/p\u003e","\u003cp\u003ePre-market development (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eFDA product submissions (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eDevelops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\u003c/p\u003e\n\u003cp\u003e- Lanham Act\u003c/p\u003e\n\u003cp\u003e- Unfair trade practice statutes (state and federal)\u003c/p\u003e","\u003cp\u003eEngages FDA and Congress on key issues related to FDA-regulated products\u003c/p\u003e","\u003cp\u003eResponds to FDA/FTC inquires, FDA warning letters, and FDA 483s\u003c/p\u003e","\u003cp\u003eExperience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics\u003c/p\u003e","\u003cp\u003eCo-Chairs Women's Health Initiative\u003c/p\u003e","\u003cp\u003eMember of Cannabis Steering Committee\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":53}]},"expertise":[{"id":2,"guid":"2.capabilities","index":0,"source":"capabilities"},{"id":3,"guid":"3.smart_tags","index":1,"source":"smartTags"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":5,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":6,"source":"smartTags"},{"id":112,"guid":"112.capabilities","index":7,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":8,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":9,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":10,"source":"smartTags"},{"id":1206,"guid":"1206.smart_tags","index":11,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":12,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":13,"source":"capabilities"}],"is_active":true,"last_name":"Dwyer","nick_name":"Lisa","clerkships":[],"first_name":"Lisa","title_rank":9999,"updated_by":202,"law_schools":[{"id":753,"meta":{"degree":"J.D.","honors":"honors","is_law_school":"1","graduation_date":"1998-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"M.","name_suffix":"","recognitions":[{"title":"Next Generation Lawyer","detail":"Legal 500, 2017 and 2019"},{"title":"Recognition for Government Relations ","detail":"Legal 500, 2016"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests ","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule ","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, FDA Language Access Plan Working Group","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)","detail":"FDA Award Ceremony, 2012"},{"title":"FDA Group Recognition Award, Menu Labeling Working Group","detail":"CFSAN/FDA Award Ceremony, 2011"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in our FDA and Life Sciences practice, Lisa has almost 25\u0026nbsp;years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco). \u0026nbsp;She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner\u0026rsquo;s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency\u0026rsquo;s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\u003c/p\u003e\n\u003cp\u003eLisa is a frequent author and speaker on topics including:\u0026nbsp; digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women\u0026rsquo;s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her \u0026ldquo;unending enthusiasm to take on client\u0026rsquo;s causes as her own.\"\u003c/p\u003e","matters":["\u003cp\u003eFocus on Digital Health/Telehealth\u003c/p\u003e","\u003cp\u003eFocus on In Vitro Diagnostic Tests and Laboratory Developed Tests\u003c/p\u003e","\u003cp\u003eFDA/FTC regulation of advertising and promotion\u003c/p\u003e","\u003cp\u003ePre-market development (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eFDA product submissions (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eDevelops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\u003c/p\u003e\n\u003cp\u003e- Lanham Act\u003c/p\u003e\n\u003cp\u003e- Unfair trade practice statutes (state and federal)\u003c/p\u003e","\u003cp\u003eEngages FDA and Congress on key issues related to FDA-regulated products\u003c/p\u003e","\u003cp\u003eResponds to FDA/FTC inquires, FDA warning letters, and FDA 483s\u003c/p\u003e","\u003cp\u003eExperience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics\u003c/p\u003e","\u003cp\u003eCo-Chairs Women's Health Initiative\u003c/p\u003e","\u003cp\u003eMember of Cannabis Steering Committee\u003c/p\u003e"],"recognitions":[{"title":"Next Generation Lawyer","detail":"Legal 500, 2017 and 2019"},{"title":"Recognition for Government Relations ","detail":"Legal 500, 2016"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests ","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule ","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, FDA Language Access Plan Working Group","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)","detail":"FDA Award Ceremony, 2012"},{"title":"FDA Group Recognition Award, Menu Labeling Working Group","detail":"CFSAN/FDA Award Ceremony, 2011"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11487}]},"capability_group_id":2},"created_at":"2025-07-09T20:54:25.000Z","updated_at":"2025-07-09T20:54:25.000Z","searchable_text":"Dwyer{{ FIELD }}{:title=\u0026gt;\"Next Generation Lawyer\", :detail=\u0026gt;\"Legal 500, 2017 and 2019\"}{{ FIELD }}{:title=\u0026gt;\"Recognition for Government Relations \", :detail=\u0026gt;\"Legal 500, 2016\"}{{ FIELD }}{:title=\u0026gt;\"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests \", :detail=\u0026gt;\"FDA Award Ceremony, 2015\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document\", :detail=\u0026gt;\"FDA Award Ceremony, 2015\"}{{ FIELD }}{:title=\u0026gt;\"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule \", :detail=\u0026gt;\"FDA Award Ceremony, 2014\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, FDA Language Access Plan Working Group\", :detail=\u0026gt;\"FDA Award Ceremony, 2014\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)\", :detail=\u0026gt;\"FDA Award Ceremony, 2012\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Menu Labeling Working Group\", :detail=\u0026gt;\"CFSAN/FDA Award Ceremony, 2011\"}{{ FIELD }}Focus on Digital Health/Telehealth{{ FIELD }}Focus on In Vitro Diagnostic Tests and Laboratory Developed Tests{{ FIELD }}FDA/FTC regulation of advertising and promotion{{ FIELD }}Pre-market development (drugs and devices (including digital health products)){{ FIELD }}FDA product submissions (drugs and devices (including digital health products)){{ FIELD }}Develops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\n- Lanham Act\n- Unfair trade practice statutes (state and federal){{ FIELD }}Engages FDA and Congress on key issues related to FDA-regulated products{{ FIELD }}Responds to FDA/FTC inquires, FDA warning letters, and FDA 483s{{ FIELD }}Experience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics{{ FIELD }}Co-Chairs Women's Health Initiative{{ FIELD }}Member of Cannabis Steering Committee{{ FIELD }}A partner in our FDA and Life Sciences practice, Lisa has almost 25 years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco).  She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.\nPreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner’s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency’s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\nLisa is a frequent author and speaker on topics including:  digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women’s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her “unending enthusiasm to take on client’s causes as her own.\" Lisa M Dwyer Partner Next Generation Lawyer Legal 500, 2017 and 2019 Recognition for Government Relations  Legal 500, 2016 FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests  FDA Award Ceremony, 2015 FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document FDA Award Ceremony, 2015 FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule  FDA Award Ceremony, 2014 FDA Group Recognition Award, FDA Language Access Plan Working Group FDA Award Ceremony, 2014 FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader) FDA Award Ceremony, 2012 FDA Group Recognition Award, Menu Labeling Working Group CFSAN/FDA Award Ceremony, 2011 Wesleyan University  George Washington University George Washington University Law School District of Columbia Massachusetts Pennsylvania Focus on Digital Health/Telehealth Focus on In Vitro Diagnostic Tests and Laboratory Developed Tests FDA/FTC regulation of advertising and promotion Pre-market development (drugs and devices (including digital health products)) FDA product submissions (drugs and devices (including digital health products)) Develops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\n- Lanham Act\n- Unfair trade practice statutes (state and federal) Engages FDA and Congress on key issues related to FDA-regulated products Responds to FDA/FTC inquires, FDA warning letters, and FDA 483s Experience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics Co-Chairs Women's Health Initiative Member of Cannabis Steering Committee","searchable_name":"Lisa M. Dwyer","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426422,"version":1,"owner_type":"Person","owner_id":3482,"payload":{"bio":"\u003cp\u003eDavid Farber specializes in litigation, regulatory matters, and public policy, with a focus on healthcare, Medicare and Medicaid issues for pharmaceutical and medical device companies, hospitals and pharmacies. A member of our FDA, Life Sciences, and Healthcare, and Government Advocacy practices, David represents clients in healthcare litigation, False Claims Act cases and other commercial disputes, as well as in advocacy before Congress and federal agencies on coverage, coding, reimbursement and other issues. He is a recognized national expert on Medicare Secondary Payer issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eCombining broad experience in litigation and public policy, David focuses on complex, multiparty litigation and government advocacy. As a lead litigator, he represents clients in a variety of healthcare and False Claims Act cases, and other disputes. He has also counseled clients in international arbitration, including matters before the International Court of Claims.\u003c/p\u003e\n\u003cp\u003eIn his advocacy practice, David focuses on advising clients in the healthcare and insurance industries. He often serves as a primary strategist and policy architect in a broad range of matters, navigating through Congress, executive branch agencies (with a focus on the Centers for Medicare \u0026amp; Medicaid Services and the Food and Drug Administration) and academia to influence the legislative and regulatory processes. Through his advocacy, he has drafted and helped pass legislation, and has prompted changes in agency policies in ways that benefit his clients. He is a national thought leader on Medicare Secondary Payer issues, having drafted the 2012 SMART Act enacted by Congress.\u003c/p\u003e","slug":"david-farber","email":"dfarber@kslaw.com","phone":"+1-240-401-4800","matters":["\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003emultiple parties, including several of the leading third-party administrators\u003c/strong\u003e, and served as lead counsel on MSP issues in U.S. ex rel. Takemoto v. Nationwide, et al, No. 16-365 (2nd Cir. January 18, 2017), dismissing first major national False Claims Act case under the Medicare Secondary Payer statute.\u003c/p\u003e","\u003cp\u003eDrafted and led strategy on behalf of the \u003cstrong data-redactor-tag=\"strong\"\u003eMARC Coalition\u003c/strong\u003e on the SMART Act, H.R. 1845 (112th Congress), enacted by Congress in 2012 as the first major reform of the Medicare Secondary Payer laws in over a decade and the SPARC Act, H.R. 1122 (115th Congress), introduced in 2017 to further improve the statute .\u003c/p\u003e","\u003cp\u003eWorked on behalf of \u003cstrong data-redactor-tag=\"strong\"\u003emajor pharmaceutical manufacturer\u003c/strong\u003e to enact Medicare Part B drug reimbursement provisions.\u003c/p\u003e","\u003cp\u003eDrafted legislation and led strategy to create federal early childhood mental health grant program.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":101}]},"expertise":[{"id":2,"guid":"2.capabilities","index":0,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":5,"source":"capabilities"},{"id":114,"guid":"114.capabilities","index":6,"source":"capabilities"},{"id":120,"guid":"120.capabilities","index":7,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":8,"source":"smartTags"},{"id":124,"guid":"124.capabilities","index":9,"source":"capabilities"}],"is_active":true,"last_name":"Farber","nick_name":"David","clerkships":[],"first_name":"David","title_rank":9999,"updated_by":101,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1987-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"J.","name_suffix":"","recognitions":[{"title":"Life Sciences Editorial Board ","detail":"Law360, 2014, 2017"},{"title":"President, Washington Region ","detail":"American Jewish Committee, 2011–2013"},{"title":"Member, National Board of Governors ","detail":"American Jewish Committee, 2013–present"},{"title":"Hyman Bookbinder Award ","detail":"American Jewish Committee, 2016"},{"title":"Bertelsmann Foundation Fellow ","detail":"German-Israel Young Leaders Exchange, 2007"},{"title":"Spirit of Community Action Award ","detail":"The United Planning Organization, 2005"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDavid Farber specializes in litigation, regulatory matters, and public policy, with a focus on healthcare, Medicare and Medicaid issues for pharmaceutical and medical device companies, hospitals and pharmacies. A member of our FDA, Life Sciences, and Healthcare, and Government Advocacy practices, David represents clients in healthcare litigation, False Claims Act cases and other commercial disputes, as well as in advocacy before Congress and federal agencies on coverage, coding, reimbursement and other issues. He is a recognized national expert on Medicare Secondary Payer issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eCombining broad experience in litigation and public policy, David focuses on complex, multiparty litigation and government advocacy. As a lead litigator, he represents clients in a variety of healthcare and False Claims Act cases, and other disputes. He has also counseled clients in international arbitration, including matters before the International Court of Claims.\u003c/p\u003e\n\u003cp\u003eIn his advocacy practice, David focuses on advising clients in the healthcare and insurance industries. He often serves as a primary strategist and policy architect in a broad range of matters, navigating through Congress, executive branch agencies (with a focus on the Centers for Medicare \u0026amp; Medicaid Services and the Food and Drug Administration) and academia to influence the legislative and regulatory processes. Through his advocacy, he has drafted and helped pass legislation, and has prompted changes in agency policies in ways that benefit his clients. He is a national thought leader on Medicare Secondary Payer issues, having drafted the 2012 SMART Act enacted by Congress.\u003c/p\u003e","matters":["\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003emultiple parties, including several of the leading third-party administrators\u003c/strong\u003e, and served as lead counsel on MSP issues in U.S. ex rel. Takemoto v. Nationwide, et al, No. 16-365 (2nd Cir. January 18, 2017), dismissing first major national False Claims Act case under the Medicare Secondary Payer statute.\u003c/p\u003e","\u003cp\u003eDrafted and led strategy on behalf of the \u003cstrong data-redactor-tag=\"strong\"\u003eMARC Coalition\u003c/strong\u003e on the SMART Act, H.R. 1845 (112th Congress), enacted by Congress in 2012 as the first major reform of the Medicare Secondary Payer laws in over a decade and the SPARC Act, H.R. 1122 (115th Congress), introduced in 2017 to further improve the statute .\u003c/p\u003e","\u003cp\u003eWorked on behalf of \u003cstrong data-redactor-tag=\"strong\"\u003emajor pharmaceutical manufacturer\u003c/strong\u003e to enact Medicare Part B drug reimbursement provisions.\u003c/p\u003e","\u003cp\u003eDrafted legislation and led strategy to create federal early childhood mental health grant program.\u003c/p\u003e"],"recognitions":[{"title":"Life Sciences Editorial Board ","detail":"Law360, 2014, 2017"},{"title":"President, Washington Region ","detail":"American Jewish Committee, 2011–2013"},{"title":"Member, National Board of Governors ","detail":"American Jewish Committee, 2013–present"},{"title":"Hyman Bookbinder Award ","detail":"American Jewish Committee, 2016"},{"title":"Bertelsmann Foundation Fellow ","detail":"German-Israel Young Leaders Exchange, 2007"},{"title":"Spirit of Community Action Award ","detail":"The United Planning Organization, 2005"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9967}]},"capability_group_id":2},"created_at":"2025-05-26T04:52:50.000Z","updated_at":"2025-05-26T04:52:50.000Z","searchable_text":"Farber{{ FIELD }}{:title=\u0026gt;\"Life Sciences Editorial Board \", :detail=\u0026gt;\"Law360, 2014, 2017\"}{{ FIELD }}{:title=\u0026gt;\"President, Washington Region \", :detail=\u0026gt;\"American Jewish Committee, 2011–2013\"}{{ FIELD }}{:title=\u0026gt;\"Member, National Board of Governors \", :detail=\u0026gt;\"American Jewish Committee, 2013–present\"}{{ FIELD }}{:title=\u0026gt;\"Hyman Bookbinder Award \", :detail=\u0026gt;\"American Jewish Committee, 2016\"}{{ FIELD }}{:title=\u0026gt;\"Bertelsmann Foundation Fellow \", :detail=\u0026gt;\"German-Israel Young Leaders Exchange, 2007\"}{{ FIELD }}{:title=\u0026gt;\"Spirit of Community Action Award \", :detail=\u0026gt;\"The United Planning Organization, 2005\"}{{ FIELD }}Represented multiple parties, including several of the leading third-party administrators, and served as lead counsel on MSP issues in U.S. ex rel. Takemoto v. Nationwide, et al, No. 16-365 (2nd Cir. January 18, 2017), dismissing first major national False Claims Act case under the Medicare Secondary Payer statute.{{ FIELD }}Drafted and led strategy on behalf of the MARC Coalition on the SMART Act, H.R. 1845 (112th Congress), enacted by Congress in 2012 as the first major reform of the Medicare Secondary Payer laws in over a decade and the SPARC Act, H.R. 1122 (115th Congress), introduced in 2017 to further improve the statute .{{ FIELD }}Worked on behalf of major pharmaceutical manufacturer to enact Medicare Part B drug reimbursement provisions.{{ FIELD }}Drafted legislation and led strategy to create federal early childhood mental health grant program.{{ FIELD }}David Farber specializes in litigation, regulatory matters, and public policy, with a focus on healthcare, Medicare and Medicaid issues for pharmaceutical and medical device companies, hospitals and pharmacies. A member of our FDA, Life Sciences, and Healthcare, and Government Advocacy practices, David represents clients in healthcare litigation, False Claims Act cases and other commercial disputes, as well as in advocacy before Congress and federal agencies on coverage, coding, reimbursement and other issues. He is a recognized national expert on Medicare Secondary Payer issues.\nCombining broad experience in litigation and public policy, David focuses on complex, multiparty litigation and government advocacy. As a lead litigator, he represents clients in a variety of healthcare and False Claims Act cases, and other disputes. He has also counseled clients in international arbitration, including matters before the International Court of Claims.\nIn his advocacy practice, David focuses on advising clients in the healthcare and insurance industries. He often serves as a primary strategist and policy architect in a broad range of matters, navigating through Congress, executive branch agencies (with a focus on the Centers for Medicare \u0026amp; Medicaid Services and the Food and Drug Administration) and academia to influence the legislative and regulatory processes. Through his advocacy, he has drafted and helped pass legislation, and has prompted changes in agency policies in ways that benefit his clients. He is a national thought leader on Medicare Secondary Payer issues, having drafted the 2012 SMART Act enacted by Congress. David J. Farber Partner Life Sciences Editorial Board  Law360, 2014, 2017 President, Washington Region  American Jewish Committee, 2011–2013 Member, National Board of Governors  American Jewish Committee, 2013–present Hyman Bookbinder Award  American Jewish Committee, 2016 Bertelsmann Foundation Fellow  German-Israel Young Leaders Exchange, 2007 Spirit of Community Action Award  The United Planning Organization, 2005 New York University New York University School of Law Georgetown University Georgetown University Law Center Supreme Court of the United States U.S. Court of Appeals for the First Circuit U.S. Court of Appeals for the Second Circuit U.S. Court of Appeals for the Third Circuit U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Fifth Circuit U.S. Court of Appeals for the Sixth Circuit U.S. Court of Appeals for the Ninth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Western District of Michigan U.S. District Court for the District of Columbia District of Columbia New York Represented multiple parties, including several of the leading third-party administrators, and served as lead counsel on MSP issues in U.S. ex rel. Takemoto v. Nationwide, et al, No. 16-365 (2nd Cir. January 18, 2017), dismissing first major national False Claims Act case under the Medicare Secondary Payer statute. Drafted and led strategy on behalf of the MARC Coalition on the SMART Act, H.R. 1845 (112th Congress), enacted by Congress in 2012 as the first major reform of the Medicare Secondary Payer laws in over a decade and the SPARC Act, H.R. 1122 (115th Congress), introduced in 2017 to further improve the statute . Worked on behalf of major pharmaceutical manufacturer to enact Medicare Part B drug reimbursement provisions. Drafted legislation and led strategy to create federal early childhood mental health grant program.","searchable_name":"David J. Farber","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":444813,"version":1,"owner_type":"Person","owner_id":3544,"payload":{"bio":"\u003cp\u003eLeah B. Grossi is a Partner on the Special Matters \u0026amp; Government Investigations team in King \u0026amp; Spalding\u0026rsquo;s Washington, D.C. office. Leah\u0026rsquo;s practice focuses on government and internal investigations, white-collar defense, and congressional investigations. With significant experience in both the public and private sectors\u0026mdash;including senior leadership positions at\u0026nbsp;the White House and the Department of Justice\u0026mdash;Leah counsels clients across industries facing complex, high-stakes matters.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eLeah advises and counsels companies and high-level executives facing government investigations and enforcement actions. Her experience includes preparing high-level witnesses for congressional hearings, conducting internal investigations, and defending individuals and companies in investigations by the Department of Justice, Securities and Exchange Commission, National Highway Traffic Safety Administration, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eLeah has held a number of high-profile positions over the course of her exemplary government service. Most recently, she served as Senior Counsel in the Office of Legislative Affairs at the Department of Justice. She also served as an Assistant United States Attorney for the U.S. Attorney\u0026rsquo;s Office for the District of Maryland (2022-2024; 2018-2021) and as an Associate Counsel for the White House Counsel\u0026rsquo;s Office (2021-2022).\u003c/p\u003e\n\u003cp\u003eLeah earned her J.D. from Georgetown Law and graduated from Johns Hopkins University with a B.A. in International Studies.\u003c/p\u003e","slug":"leah-grossi","email":"lgrossi@kslaw.com","phone":null,"matters":["\u003cp\u003ePrepared high-level government witnesses for congressional hearings and briefings, including U.S. Attorney General Merrick B. Garland, U.S. Supreme Court Associate Justice Ketanji Brown Jackson, and Special Counsel Robert K. Hur.\u003c/p\u003e","\u003cp\u003eRepresented a major U.S. bank in a high-profile investigation by the Department of Justice into the origination and sale of residential mortgage backed securities.\u003c/p\u003e","\u003cp\u003eRepresented leading automobile manufacturers in connection with government investigations and multi-jurisdictional civil litigation relating to a series of high-profile vehicle recalls.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong\u003eJPMorgan Chase\u003c/strong\u003e in the first bank civil lawsuit arising out of the subprime mortgage financial crisis. \u003cstrong\u003eJPMorgan Chase\u003c/strong\u003e won summary judgment on all of its claims in a federal fraud and breach of fiduciary duty lawsuit brought by Bank of America against JPMorgan Chase\u0026rsquo;s Bear Stearns Asset Management (\"BSAM\") unit in connection with a $4 billion collateralized debt obligation transaction.\u003c/p\u003e","\u003cp\u003eServed as General Counsel for the \u003cstrong\u003eEthics and Compliance Initiative\u003c/strong\u003e, an organization that is committed to creating and sustaining high quality ethics and compliance programs throughout the world.\u003c/p\u003e","\u003cp\u003eRepresented the Creditors Committee in the \u003cstrong\u003eMagna Entertainment\u003c/strong\u003e bankruptcy in litigation concerning the recharacterization of debt and equitable subordination claims.\u003c/p\u003e","\u003cp\u003eRepresented individuals and corporations in Department of Justice, National Highway Traffic Safety Administration, Securities and Exchange Commission, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance investigations.\u003c/p\u003e","\u003cp\u003eAs an Assistant United States Attorney, prosecuted and investigated a wide variety of federal criminal matters, including cases involving wire and bank fraud, money laundering, identity theft, false tax preparation and returns, government contract fraud, theft of government property, and graft.\u003c/p\u003e","\u003cp\u003eServed as lead counsel on a wide variety of state criminal matters on behalf of The Legal Aid Society Criminal Defense Division in Manhattan.\u003c/p\u003e","\u003cp\u003eRepresented the Bronx Bureau of the New York City Law Department, Office of the Corporation Counsel as a Public Service Attorney.\u003c/p\u003e","\u003cp\u003eRepresented several Uighurs, a persecuted Muslim minority group from western China, who were wrongfully imprisoned at Guantanamo Bay.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":106,"guid":"106.capabilities","index":0,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":1,"source":"smartTags"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":3,"source":"capabilities"},{"id":766,"guid":"766.smart_tags","index":4,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":5,"source":"smartTags"},{"id":11,"guid":"11.capabilities","index":6,"source":"capabilities"},{"id":111,"guid":"111.capabilities","index":7,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":8,"source":"capabilities"}],"is_active":true,"last_name":"Grossi","nick_name":"Leah","clerkships":[],"first_name":"Leah","title_rank":9999,"updated_by":202,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2009-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"B.","name_suffix":"","recognitions":[{"title":"Co-chaired the King \u0026 Spalding Women In Compliance Summit","detail":"2017 and 2018"},{"title":"Under 40 Hot List","detail":"Benchmark Litigation, 2017 and 2018"},{"title":"White Collar Editorial Advisory Board","detail":"Law360, 2017"},{"title":"Pro Bono Publico Award","detail":"The Legal Aid Society, 2013"},{"title":"Sanctuary Award for Excellence in Pro Bono Advocacy","detail":"Sanctuary for Families, 2011"}],"linked_in_url":"https://www.linkedin.com/in/leah-grossi-72170524/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eLeah B. Grossi is a Partner on the Special Matters \u0026amp; Government Investigations team in King \u0026amp; Spalding\u0026rsquo;s Washington, D.C. office. Leah\u0026rsquo;s practice focuses on government and internal investigations, white-collar defense, and congressional investigations. With significant experience in both the public and private sectors\u0026mdash;including senior leadership positions at\u0026nbsp;the White House and the Department of Justice\u0026mdash;Leah counsels clients across industries facing complex, high-stakes matters.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eLeah advises and counsels companies and high-level executives facing government investigations and enforcement actions. Her experience includes preparing high-level witnesses for congressional hearings, conducting internal investigations, and defending individuals and companies in investigations by the Department of Justice, Securities and Exchange Commission, National Highway Traffic Safety Administration, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eLeah has held a number of high-profile positions over the course of her exemplary government service. Most recently, she served as Senior Counsel in the Office of Legislative Affairs at the Department of Justice. She also served as an Assistant United States Attorney for the U.S. Attorney\u0026rsquo;s Office for the District of Maryland (2022-2024; 2018-2021) and as an Associate Counsel for the White House Counsel\u0026rsquo;s Office (2021-2022).\u003c/p\u003e\n\u003cp\u003eLeah earned her J.D. from Georgetown Law and graduated from Johns Hopkins University with a B.A. in International Studies.\u003c/p\u003e","matters":["\u003cp\u003ePrepared high-level government witnesses for congressional hearings and briefings, including U.S. Attorney General Merrick B. Garland, U.S. Supreme Court Associate Justice Ketanji Brown Jackson, and Special Counsel Robert K. Hur.\u003c/p\u003e","\u003cp\u003eRepresented a major U.S. bank in a high-profile investigation by the Department of Justice into the origination and sale of residential mortgage backed securities.\u003c/p\u003e","\u003cp\u003eRepresented leading automobile manufacturers in connection with government investigations and multi-jurisdictional civil litigation relating to a series of high-profile vehicle recalls.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong\u003eJPMorgan Chase\u003c/strong\u003e in the first bank civil lawsuit arising out of the subprime mortgage financial crisis. \u003cstrong\u003eJPMorgan Chase\u003c/strong\u003e won summary judgment on all of its claims in a federal fraud and breach of fiduciary duty lawsuit brought by Bank of America against JPMorgan Chase\u0026rsquo;s Bear Stearns Asset Management (\"BSAM\") unit in connection with a $4 billion collateralized debt obligation transaction.\u003c/p\u003e","\u003cp\u003eServed as General Counsel for the \u003cstrong\u003eEthics and Compliance Initiative\u003c/strong\u003e, an organization that is committed to creating and sustaining high quality ethics and compliance programs throughout the world.\u003c/p\u003e","\u003cp\u003eRepresented the Creditors Committee in the \u003cstrong\u003eMagna Entertainment\u003c/strong\u003e bankruptcy in litigation concerning the recharacterization of debt and equitable subordination claims.\u003c/p\u003e","\u003cp\u003eRepresented individuals and corporations in Department of Justice, National Highway Traffic Safety Administration, Securities and Exchange Commission, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance investigations.\u003c/p\u003e","\u003cp\u003eAs an Assistant United States Attorney, prosecuted and investigated a wide variety of federal criminal matters, including cases involving wire and bank fraud, money laundering, identity theft, false tax preparation and returns, government contract fraud, theft of government property, and graft.\u003c/p\u003e","\u003cp\u003eServed as lead counsel on a wide variety of state criminal matters on behalf of The Legal Aid Society Criminal Defense Division in Manhattan.\u003c/p\u003e","\u003cp\u003eRepresented the Bronx Bureau of the New York City Law Department, Office of the Corporation Counsel as a Public Service Attorney.\u003c/p\u003e","\u003cp\u003eRepresented several Uighurs, a persecuted Muslim minority group from western China, who were wrongfully imprisoned at Guantanamo Bay.\u003c/p\u003e"],"recognitions":[{"title":"Co-chaired the King \u0026 Spalding Women In Compliance Summit","detail":"2017 and 2018"},{"title":"Under 40 Hot List","detail":"Benchmark Litigation, 2017 and 2018"},{"title":"White Collar Editorial Advisory Board","detail":"Law360, 2017"},{"title":"Pro Bono Publico Award","detail":"The Legal Aid Society, 2013"},{"title":"Sanctuary Award for Excellence in Pro Bono Advocacy","detail":"Sanctuary for Families, 2011"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12085}]},"capability_group_id":2},"created_at":"2026-01-06T18:13:53.000Z","updated_at":"2026-01-06T18:13:53.000Z","searchable_text":"Grossi{{ FIELD }}{:title=\u0026gt;\"Co-chaired the King \u0026amp; Spalding Women In Compliance Summit\", :detail=\u0026gt;\"2017 and 2018\"}{{ FIELD }}{:title=\u0026gt;\"Under 40 Hot List\", :detail=\u0026gt;\"Benchmark Litigation, 2017 and 2018\"}{{ FIELD }}{:title=\u0026gt;\"White Collar Editorial Advisory Board\", :detail=\u0026gt;\"Law360, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Pro Bono Publico Award\", :detail=\u0026gt;\"The Legal Aid Society, 2013\"}{{ FIELD }}{:title=\u0026gt;\"Sanctuary Award for Excellence in Pro Bono Advocacy\", :detail=\u0026gt;\"Sanctuary for Families, 2011\"}{{ FIELD }}Prepared high-level government witnesses for congressional hearings and briefings, including U.S. Attorney General Merrick B. Garland, U.S. Supreme Court Associate Justice Ketanji Brown Jackson, and Special Counsel Robert K. Hur.{{ FIELD }}Represented a major U.S. bank in a high-profile investigation by the Department of Justice into the origination and sale of residential mortgage backed securities.{{ FIELD }}Represented leading automobile manufacturers in connection with government investigations and multi-jurisdictional civil litigation relating to a series of high-profile vehicle recalls.{{ FIELD }}Represented JPMorgan Chase in the first bank civil lawsuit arising out of the subprime mortgage financial crisis. JPMorgan Chase won summary judgment on all of its claims in a federal fraud and breach of fiduciary duty lawsuit brought by Bank of America against JPMorgan Chase’s Bear Stearns Asset Management (\"BSAM\") unit in connection with a $4 billion collateralized debt obligation transaction.{{ FIELD }}Served as General Counsel for the Ethics and Compliance Initiative, an organization that is committed to creating and sustaining high quality ethics and compliance programs throughout the world.{{ FIELD }}Represented the Creditors Committee in the Magna Entertainment bankruptcy in litigation concerning the recharacterization of debt and equitable subordination claims.{{ FIELD }}Represented individuals and corporations in Department of Justice, National Highway Traffic Safety Administration, Securities and Exchange Commission, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance investigations.{{ FIELD }}As an Assistant United States Attorney, prosecuted and investigated a wide variety of federal criminal matters, including cases involving wire and bank fraud, money laundering, identity theft, false tax preparation and returns, government contract fraud, theft of government property, and graft.{{ FIELD }}Served as lead counsel on a wide variety of state criminal matters on behalf of The Legal Aid Society Criminal Defense Division in Manhattan.{{ FIELD }}Represented the Bronx Bureau of the New York City Law Department, Office of the Corporation Counsel as a Public Service Attorney.{{ FIELD }}Represented several Uighurs, a persecuted Muslim minority group from western China, who were wrongfully imprisoned at Guantanamo Bay.{{ FIELD }}Leah B. Grossi is a Partner on the Special Matters \u0026amp; Government Investigations team in King \u0026amp; Spalding’s Washington, D.C. office. Leah’s practice focuses on government and internal investigations, white-collar defense, and congressional investigations. With significant experience in both the public and private sectors—including senior leadership positions at the White House and the Department of Justice—Leah counsels clients across industries facing complex, high-stakes matters. \nLeah advises and counsels companies and high-level executives facing government investigations and enforcement actions. Her experience includes preparing high-level witnesses for congressional hearings, conducting internal investigations, and defending individuals and companies in investigations by the Department of Justice, Securities and Exchange Commission, National Highway Traffic Safety Administration, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance.  \nLeah has held a number of high-profile positions over the course of her exemplary government service. Most recently, she served as Senior Counsel in the Office of Legislative Affairs at the Department of Justice. She also served as an Assistant United States Attorney for the U.S. Attorney’s Office for the District of Maryland (2022-2024; 2018-2021) and as an Associate Counsel for the White House Counsel’s Office (2021-2022).\nLeah earned her J.D. from Georgetown Law and graduated from Johns Hopkins University with a B.A. in International Studies. Partner Co-chaired the King \u0026amp; Spalding Women In Compliance Summit 2017 and 2018 Under 40 Hot List Benchmark Litigation, 2017 and 2018 White Collar Editorial Advisory Board Law360, 2017 Pro Bono Publico Award The Legal Aid Society, 2013 Sanctuary Award for Excellence in Pro Bono Advocacy Sanctuary for Families, 2011 Johns Hopkins University  Georgetown University Georgetown University Law Center U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York U.S. District Court for the District of Columbia District of Columbia New York Women's White Collar Defense Association Edward Bennett Williams Inn of Court Prepared high-level government witnesses for congressional hearings and briefings, including U.S. Attorney General Merrick B. Garland, U.S. Supreme Court Associate Justice Ketanji Brown Jackson, and Special Counsel Robert K. Hur. Represented a major U.S. bank in a high-profile investigation by the Department of Justice into the origination and sale of residential mortgage backed securities. Represented leading automobile manufacturers in connection with government investigations and multi-jurisdictional civil litigation relating to a series of high-profile vehicle recalls. Represented JPMorgan Chase in the first bank civil lawsuit arising out of the subprime mortgage financial crisis. JPMorgan Chase won summary judgment on all of its claims in a federal fraud and breach of fiduciary duty lawsuit brought by Bank of America against JPMorgan Chase’s Bear Stearns Asset Management (\"BSAM\") unit in connection with a $4 billion collateralized debt obligation transaction. Served as General Counsel for the Ethics and Compliance Initiative, an organization that is committed to creating and sustaining high quality ethics and compliance programs throughout the world. Represented the Creditors Committee in the Magna Entertainment bankruptcy in litigation concerning the recharacterization of debt and equitable subordination claims. Represented individuals and corporations in Department of Justice, National Highway Traffic Safety Administration, Securities and Exchange Commission, Commodity Futures Trading Commission, New York Attorney General, and New York Department of Taxation and Finance investigations. As an Assistant United States Attorney, prosecuted and investigated a wide variety of federal criminal matters, including cases involving wire and bank fraud, money laundering, identity theft, false tax preparation and returns, government contract fraud, theft of government property, and graft. Served as lead counsel on a wide variety of state criminal matters on behalf of The Legal Aid Society Criminal Defense Division in Manhattan. Represented the Bronx Bureau of the New York City Law Department, Office of the Corporation Counsel as a Public Service Attorney. Represented several Uighurs, a persecuted Muslim minority group from western China, who were wrongfully imprisoned at Guantanamo Bay.","searchable_name":"Leah B. Grossi","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":445483,"version":1,"owner_type":"Person","owner_id":3538,"payload":{"bio":"\u003cp\u003eFormer Deputy Assistant Attorney General Matt Hanson represents companies and individuals in government investigations by Congress, the Securities and Exchange Commission (SEC), the Department of Justice (DOJ), and other federal and state regulators. Matt also counsels clients on related disclosure and regulatory issues and helps conduct internal investigations to assess potential liability before the government becomes involved. He is a partner in King \u0026amp; Spalding\u0026rsquo;s Special Matters \u0026amp; Government Investigations practice.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMatt has particular experience with congressional inquiries\u0026mdash;both responding to large-scale investigations and helping manage low-key initial requests. He has prepared senior executives for dozens of public hearings and managed responses to high-pressure House and Senate inquiries. Many high-profile congressional matters are accompanied by parallel investigations from other regulators, and Matt has deep experience representing clients in the tech, finance, and healthcare spaces, among other industries, facing such enterprise-threatening regulatory investigations. As a former reporter, Matt also helps clients manage broader impacts that investigations can have on their business.\u003c/p\u003e\n\u003cp\u003eMatt served nearly three years with DOJ\u0026rsquo;s Office of Legislative Affairs, most recently as a Deputy Assistant Attorney General. While in that role, Matt handled sensitive congressional requests and investigations directed at the Department and prepared senior leadership for testimony, including the Attorney General. He worked closely with other DOJ leadership offices and with DOJ\u0026rsquo;s National Security Division, the FBI, and the Drug Enforcement Administration, managing the Department\u0026rsquo;s engagement with Congress on issues, cases, and legislation affecting national security. He engaged regularly with House and Senate committees focused on the judiciary, financial services, intelligence, and healthcare, as well as with House and Senate leadership staff.\u003c/p\u003e\n\u003cp\u003eBefore his government service, Matt had\u0026nbsp;over a decade of private practice experience representing clients facing securities enforcement and other tech and white-collar investigations. Matt\u0026rsquo;s clients include public companies, social media platforms, emerging tech companies, broker-dealers, investment advisers, and financial institutions, as well as corporate officers and other individuals. He previously helped lead the firm\u0026rsquo;s work for clients in the digital assets space.\u003c/p\u003e\n\u003cp\u003eBefore becoming a lawyer, Matt worked as a news reporter covering bonds, structured finance, and other financial markets.\u003c/p\u003e","slug":"matthew-hanson","email":"mhanson@kslaw.com","phone":"+1 202 417 1883","matters":["\u003cp\u003eCompanies, corporate executives, and senior government officials in congressional oversight investigations before House and Senate committees on a wide range of issues, including competition laws, online content moderation, national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement\u003c/p\u003e","\u003cp\u003eCompanies and individuals before the SEC, DOJ, and state attorneys general in both discrete non-public matters, as well as high-profile parallel investigations\u003c/p\u003e","\u003cp\u003eMultiple blockchain-related start-ups and established companies in connection with SEC document and information requests\u003c/p\u003e","\u003cp\u003eCompanies conducting internal reviews to assess their risk of liability and implement proactive remediation to help avoid costly government investigations\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eCongressional Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eGlobal technology company before House and Senate Judiciary Committees in investigations of competition issues relating to \u0026ldquo;Big Tech\u0026rdquo;\u003c/p\u003e","\u003cp\u003eGlobal technology company in responding to House January 6th Select Committee\u003c/p\u003e","\u003cp\u003eFinancial services firms in government inquiries arising out of multiple large-scale cybersecurity incidents, including before the Senate Permanent Subcommittee on Investigations, the House Committee on Oversight and Reform, and the House Committee on Energy and Commerce\u003c/p\u003e","\u003cp\u003eSenior DOJ officials in multiple transcribed witness interviews in connection with investigations by House and Senate committees\u003c/p\u003e","\u003cp\u003ePrepared many senior DOJ officials for public hearing testimony before a variety of congressional committees, including: the Attorney General; multiple senior FBI officials; multiple senior officials from DOJ\u0026rsquo;s National Security Division; multiple senior officials from DOJ\u0026rsquo;s Criminal Division; Administrator of the U.S. Drug Enforcement Administration; Director of the Bureau of Alcohol, Tobacco, Firearms and Explosives; Director of the U.S. Marshals Service; Director of the Federal Bureau of Prisons; Director of DOJ\u0026rsquo;s COVID-19 Fraud Enforcement Task Force; and the acting head of DOJ\u0026rsquo;s Office of Justice Programs\u003c/p\u003e","\u003cp\u003eResponded to hundreds of congressional request letters to DOJ on a wide range of issues, including national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement\u003c/p\u003e","\u003cp\u003eDOJ subject matter experts in dozens of substantive briefings (in both classified and unclassified settings) to members of Congress and senior staff of various committees, including the House Select Committee on the CCP\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eSecurities and White-Collar Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003ePublicly traded healthcare company in an SEC investigation of possible accounting fraud\u003c/p\u003e","\u003cp\u003eTurnkey asset management platform in multiple SEC investigations of leveraged ETF trades and separate allegations by former employees\u003c/p\u003e","\u003cp\u003eMultinational financial institution in a Financial Fraud Enforcement Task Force investigation relating to residential mortgage-backed securities disclosures\u003c/p\u003e","\u003cp\u003eConducted internal investigation for government-owned energy company regarding compliance with anti-bribery laws\u003c/p\u003e","\u003cp\u003eAdvised Japanese affiliate of big-four international audit firm on U.S. auditor independence rules\u003c/p\u003e","\u003cp\u003eBroker-dealer in parallel SEC and FINRA investigations of possible layering and spoofing trades\u003c/p\u003e","\u003cp\u003eGlobal technology company before state attorneys general investigating content moderation issues\u003c/p\u003e","\u003cp\u003eTelecommunications company in state attorney general False Claims Act investigation\u003c/p\u003e","\u003cp\u003eVariety of other clients in responding to the SEC on issues including investigative testimony, post-merger insider trading questions, revolving-door ethics rules, and third-party witness testimony in SEC litigation\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eDigital Assets and Emerging Technology\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eDigital asset fund manager in connection with an SEC enforcement inquiry and as a witness in a separate SEC investigation\u003c/p\u003e","\u003cp\u003eServed as acting general counsel for client during transition of in-house legal function\u003c/p\u003e","\u003cp\u003eProvided guidance to start-up ventures on potential regulatory and enforcement risk\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":20,"guid":"20.capabilities","index":0,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":1,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":765,"guid":"765.smart_tags","index":3,"source":"smartTags"},{"id":687,"guid":"687.smart_tags","index":4,"source":"smartTags"},{"id":110,"guid":"110.capabilities","index":5,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":6,"source":"capabilities"},{"id":133,"guid":"133.capabilities","index":7,"source":"capabilities"},{"id":111,"guid":"111.capabilities","index":8,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":9,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":10,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":11,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Hanson","nick_name":"Matthew","clerkships":[],"first_name":"Matthew","title_rank":9999,"updated_by":202,"law_schools":[{"id":2410,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2011-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"B.","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/matt-hanson-1286b516","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eFormer Deputy Assistant Attorney General Matt Hanson represents companies and individuals in government investigations by Congress, the Securities and Exchange Commission (SEC), the Department of Justice (DOJ), and other federal and state regulators. Matt also counsels clients on related disclosure and regulatory issues and helps conduct internal investigations to assess potential liability before the government becomes involved. He is a partner in King \u0026amp; Spalding\u0026rsquo;s Special Matters \u0026amp; Government Investigations practice.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMatt has particular experience with congressional inquiries\u0026mdash;both responding to large-scale investigations and helping manage low-key initial requests. He has prepared senior executives for dozens of public hearings and managed responses to high-pressure House and Senate inquiries. Many high-profile congressional matters are accompanied by parallel investigations from other regulators, and Matt has deep experience representing clients in the tech, finance, and healthcare spaces, among other industries, facing such enterprise-threatening regulatory investigations. As a former reporter, Matt also helps clients manage broader impacts that investigations can have on their business.\u003c/p\u003e\n\u003cp\u003eMatt served nearly three years with DOJ\u0026rsquo;s Office of Legislative Affairs, most recently as a Deputy Assistant Attorney General. While in that role, Matt handled sensitive congressional requests and investigations directed at the Department and prepared senior leadership for testimony, including the Attorney General. He worked closely with other DOJ leadership offices and with DOJ\u0026rsquo;s National Security Division, the FBI, and the Drug Enforcement Administration, managing the Department\u0026rsquo;s engagement with Congress on issues, cases, and legislation affecting national security. He engaged regularly with House and Senate committees focused on the judiciary, financial services, intelligence, and healthcare, as well as with House and Senate leadership staff.\u003c/p\u003e\n\u003cp\u003eBefore his government service, Matt had\u0026nbsp;over a decade of private practice experience representing clients facing securities enforcement and other tech and white-collar investigations. Matt\u0026rsquo;s clients include public companies, social media platforms, emerging tech companies, broker-dealers, investment advisers, and financial institutions, as well as corporate officers and other individuals. He previously helped lead the firm\u0026rsquo;s work for clients in the digital assets space.\u003c/p\u003e\n\u003cp\u003eBefore becoming a lawyer, Matt worked as a news reporter covering bonds, structured finance, and other financial markets.\u003c/p\u003e","matters":["\u003cp\u003eCompanies, corporate executives, and senior government officials in congressional oversight investigations before House and Senate committees on a wide range of issues, including competition laws, online content moderation, national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement\u003c/p\u003e","\u003cp\u003eCompanies and individuals before the SEC, DOJ, and state attorneys general in both discrete non-public matters, as well as high-profile parallel investigations\u003c/p\u003e","\u003cp\u003eMultiple blockchain-related start-ups and established companies in connection with SEC document and information requests\u003c/p\u003e","\u003cp\u003eCompanies conducting internal reviews to assess their risk of liability and implement proactive remediation to help avoid costly government investigations\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eCongressional Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eGlobal technology company before House and Senate Judiciary Committees in investigations of competition issues relating to \u0026ldquo;Big Tech\u0026rdquo;\u003c/p\u003e","\u003cp\u003eGlobal technology company in responding to House January 6th Select Committee\u003c/p\u003e","\u003cp\u003eFinancial services firms in government inquiries arising out of multiple large-scale cybersecurity incidents, including before the Senate Permanent Subcommittee on Investigations, the House Committee on Oversight and Reform, and the House Committee on Energy and Commerce\u003c/p\u003e","\u003cp\u003eSenior DOJ officials in multiple transcribed witness interviews in connection with investigations by House and Senate committees\u003c/p\u003e","\u003cp\u003ePrepared many senior DOJ officials for public hearing testimony before a variety of congressional committees, including: the Attorney General; multiple senior FBI officials; multiple senior officials from DOJ\u0026rsquo;s National Security Division; multiple senior officials from DOJ\u0026rsquo;s Criminal Division; Administrator of the U.S. Drug Enforcement Administration; Director of the Bureau of Alcohol, Tobacco, Firearms and Explosives; Director of the U.S. Marshals Service; Director of the Federal Bureau of Prisons; Director of DOJ\u0026rsquo;s COVID-19 Fraud Enforcement Task Force; and the acting head of DOJ\u0026rsquo;s Office of Justice Programs\u003c/p\u003e","\u003cp\u003eResponded to hundreds of congressional request letters to DOJ on a wide range of issues, including national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement\u003c/p\u003e","\u003cp\u003eDOJ subject matter experts in dozens of substantive briefings (in both classified and unclassified settings) to members of Congress and senior staff of various committees, including the House Select Committee on the CCP\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eSecurities and White-Collar Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003ePublicly traded healthcare company in an SEC investigation of possible accounting fraud\u003c/p\u003e","\u003cp\u003eTurnkey asset management platform in multiple SEC investigations of leveraged ETF trades and separate allegations by former employees\u003c/p\u003e","\u003cp\u003eMultinational financial institution in a Financial Fraud Enforcement Task Force investigation relating to residential mortgage-backed securities disclosures\u003c/p\u003e","\u003cp\u003eConducted internal investigation for government-owned energy company regarding compliance with anti-bribery laws\u003c/p\u003e","\u003cp\u003eAdvised Japanese affiliate of big-four international audit firm on U.S. auditor independence rules\u003c/p\u003e","\u003cp\u003eBroker-dealer in parallel SEC and FINRA investigations of possible layering and spoofing trades\u003c/p\u003e","\u003cp\u003eGlobal technology company before state attorneys general investigating content moderation issues\u003c/p\u003e","\u003cp\u003eTelecommunications company in state attorney general False Claims Act investigation\u003c/p\u003e","\u003cp\u003eVariety of other clients in responding to the SEC on issues including investigative testimony, post-merger insider trading questions, revolving-door ethics rules, and third-party witness testimony in SEC litigation\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eDigital Assets and Emerging Technology\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eDigital asset fund manager in connection with an SEC enforcement inquiry and as a witness in a separate SEC investigation\u003c/p\u003e","\u003cp\u003eServed as acting general counsel for client during transition of in-house legal function\u003c/p\u003e","\u003cp\u003eProvided guidance to start-up ventures on potential regulatory and enforcement risk\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12886}]},"capability_group_id":2},"created_at":"2026-02-02T20:11:14.000Z","updated_at":"2026-02-02T20:11:14.000Z","searchable_text":"Hanson{{ FIELD }}Companies, corporate executives, and senior government officials in congressional oversight investigations before House and Senate committees on a wide range of issues, including competition laws, online content moderation, national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement{{ FIELD }}Companies and individuals before the SEC, DOJ, and state attorneys general in both discrete non-public matters, as well as high-profile parallel investigations{{ FIELD }}Multiple blockchain-related start-ups and established companies in connection with SEC document and information requests{{ FIELD }}Companies conducting internal reviews to assess their risk of liability and implement proactive remediation to help avoid costly government investigations{{ FIELD }}Congressional Investigations{{ FIELD }}Global technology company before House and Senate Judiciary Committees in investigations of competition issues relating to “Big Tech”{{ FIELD }}Global technology company in responding to House January 6th Select Committee{{ FIELD }}Financial services firms in government inquiries arising out of multiple large-scale cybersecurity incidents, including before the Senate Permanent Subcommittee on Investigations, the House Committee on Oversight and Reform, and the House Committee on Energy and Commerce{{ FIELD }}Senior DOJ officials in multiple transcribed witness interviews in connection with investigations by House and Senate committees{{ FIELD }}Prepared many senior DOJ officials for public hearing testimony before a variety of congressional committees, including: the Attorney General; multiple senior FBI officials; multiple senior officials from DOJ’s National Security Division; multiple senior officials from DOJ’s Criminal Division; Administrator of the U.S. Drug Enforcement Administration; Director of the Bureau of Alcohol, Tobacco, Firearms and Explosives; Director of the U.S. Marshals Service; Director of the Federal Bureau of Prisons; Director of DOJ’s COVID-19 Fraud Enforcement Task Force; and the acting head of DOJ’s Office of Justice Programs{{ FIELD }}Responded to hundreds of congressional request letters to DOJ on a wide range of issues, including national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement{{ FIELD }}DOJ subject matter experts in dozens of substantive briefings (in both classified and unclassified settings) to members of Congress and senior staff of various committees, including the House Select Committee on the CCP{{ FIELD }}Securities and White-Collar Investigations{{ FIELD }}Publicly traded healthcare company in an SEC investigation of possible accounting fraud{{ FIELD }}Turnkey asset management platform in multiple SEC investigations of leveraged ETF trades and separate allegations by former employees{{ FIELD }}Multinational financial institution in a Financial Fraud Enforcement Task Force investigation relating to residential mortgage-backed securities disclosures{{ FIELD }}Conducted internal investigation for government-owned energy company regarding compliance with anti-bribery laws{{ FIELD }}Advised Japanese affiliate of big-four international audit firm on U.S. auditor independence rules{{ FIELD }}Broker-dealer in parallel SEC and FINRA investigations of possible layering and spoofing trades{{ FIELD }}Global technology company before state attorneys general investigating content moderation issues{{ FIELD }}Telecommunications company in state attorney general False Claims Act investigation{{ FIELD }}Variety of other clients in responding to the SEC on issues including investigative testimony, post-merger insider trading questions, revolving-door ethics rules, and third-party witness testimony in SEC litigation{{ FIELD }}Digital Assets and Emerging Technology{{ FIELD }}Digital asset fund manager in connection with an SEC enforcement inquiry and as a witness in a separate SEC investigation{{ FIELD }}Served as acting general counsel for client during transition of in-house legal function{{ FIELD }}Provided guidance to start-up ventures on potential regulatory and enforcement risk{{ FIELD }}Former Deputy Assistant Attorney General Matt Hanson represents companies and individuals in government investigations by Congress, the Securities and Exchange Commission (SEC), the Department of Justice (DOJ), and other federal and state regulators. Matt also counsels clients on related disclosure and regulatory issues and helps conduct internal investigations to assess potential liability before the government becomes involved. He is a partner in King \u0026amp; Spalding’s Special Matters \u0026amp; Government Investigations practice. \nMatt has particular experience with congressional inquiries—both responding to large-scale investigations and helping manage low-key initial requests. He has prepared senior executives for dozens of public hearings and managed responses to high-pressure House and Senate inquiries. Many high-profile congressional matters are accompanied by parallel investigations from other regulators, and Matt has deep experience representing clients in the tech, finance, and healthcare spaces, among other industries, facing such enterprise-threatening regulatory investigations. As a former reporter, Matt also helps clients manage broader impacts that investigations can have on their business.\nMatt served nearly three years with DOJ’s Office of Legislative Affairs, most recently as a Deputy Assistant Attorney General. While in that role, Matt handled sensitive congressional requests and investigations directed at the Department and prepared senior leadership for testimony, including the Attorney General. He worked closely with other DOJ leadership offices and with DOJ’s National Security Division, the FBI, and the Drug Enforcement Administration, managing the Department’s engagement with Congress on issues, cases, and legislation affecting national security. He engaged regularly with House and Senate committees focused on the judiciary, financial services, intelligence, and healthcare, as well as with House and Senate leadership staff.\nBefore his government service, Matt had over a decade of private practice experience representing clients facing securities enforcement and other tech and white-collar investigations. Matt’s clients include public companies, social media platforms, emerging tech companies, broker-dealers, investment advisers, and financial institutions, as well as corporate officers and other individuals. He previously helped lead the firm’s work for clients in the digital assets space.\nBefore becoming a lawyer, Matt worked as a news reporter covering bonds, structured finance, and other financial markets. Partner University of North Carolina at Chapel Hill University of North Carolina School of Law University of Virginia University of Virginia School of Law U.S. District Court for the Eastern District of Virginia District of Columbia Virginia American Bar Association Companies, corporate executives, and senior government officials in congressional oversight investigations before House and Senate committees on a wide range of issues, including competition laws, online content moderation, national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement Companies and individuals before the SEC, DOJ, and state attorneys general in both discrete non-public matters, as well as high-profile parallel investigations Multiple blockchain-related start-ups and established companies in connection with SEC document and information requests Companies conducting internal reviews to assess their risk of liability and implement proactive remediation to help avoid costly government investigations Congressional Investigations Global technology company before House and Senate Judiciary Committees in investigations of competition issues relating to “Big Tech” Global technology company in responding to House January 6th Select Committee Financial services firms in government inquiries arising out of multiple large-scale cybersecurity incidents, including before the Senate Permanent Subcommittee on Investigations, the House Committee on Oversight and Reform, and the House Committee on Energy and Commerce Senior DOJ officials in multiple transcribed witness interviews in connection with investigations by House and Senate committees Prepared many senior DOJ officials for public hearing testimony before a variety of congressional committees, including: the Attorney General; multiple senior FBI officials; multiple senior officials from DOJ’s National Security Division; multiple senior officials from DOJ’s Criminal Division; Administrator of the U.S. Drug Enforcement Administration; Director of the Bureau of Alcohol, Tobacco, Firearms and Explosives; Director of the U.S. Marshals Service; Director of the Federal Bureau of Prisons; Director of DOJ’s COVID-19 Fraud Enforcement Task Force; and the acting head of DOJ’s Office of Justice Programs Responded to hundreds of congressional request letters to DOJ on a wide range of issues, including national security, criminal and civil investigations, data privacy, cybersecurity, digital assets, and federal drug enforcement DOJ subject matter experts in dozens of substantive briefings (in both classified and unclassified settings) to members of Congress and senior staff of various committees, including the House Select Committee on the CCP Securities and White-Collar Investigations Publicly traded healthcare company in an SEC investigation of possible accounting fraud Turnkey asset management platform in multiple SEC investigations of leveraged ETF trades and separate allegations by former employees Multinational financial institution in a Financial Fraud Enforcement Task Force investigation relating to residential mortgage-backed securities disclosures Conducted internal investigation for government-owned energy company regarding compliance with anti-bribery laws Advised Japanese affiliate of big-four international audit firm on U.S. auditor independence rules Broker-dealer in parallel SEC and FINRA investigations of possible layering and spoofing trades Global technology company before state attorneys general investigating content moderation issues Telecommunications company in state attorney general False Claims Act investigation Variety of other clients in responding to the SEC on issues including investigative testimony, post-merger insider trading questions, revolving-door ethics rules, and third-party witness testimony in SEC litigation Digital Assets and Emerging Technology Digital asset fund manager in connection with an SEC enforcement inquiry and as a witness in a separate SEC investigation Served as acting general counsel for client during transition of in-house legal function Provided guidance to start-up ventures on potential regulatory and enforcement risk","searchable_name":"Matthew B. Hanson","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}